


 ISTITUTO PER LO STUDIO E LA PREVENZIONE ONCOLOGICA	Procedura	Codice Aziendale CP004
	IMMUNOCITOCHIMICA	Pag. 1 di 7
	S.S. Laboratorio Regionale HPV e Biologia Molecolare	Ed. 2 Rev. 0

Gruppo di redazione: Cristina Maddau, Francesca Carozzi

	NOME	FUNZIONE	DATA	FIRMA
REDAZIONE	Cristina Maddau	Biologo Dirigente	10/01/2017	
VERIFICA	Guido Castiglione	Referente per la Qualità e l'Accreditamento	12/01/2017	
APPROVAZIONE	Riccardo Poli	Direttore Sanitario	20/03/2017	

INDICE

1. SCOPO	pag. 3
2. CAMPO DI APPLICAZIONE	pag. 3
3. TERMINOLOGIA E ABBREVIAZIONI	pag. 3
4. RESPONSABILITÀ	pag. 4
5. DESCRIZIONE DELLE ATTIVITÀ	pag. 4
6. RIFERIMENTI	pag. 7
7. ALLEGATI	pag. 7
8. APPARECCHIATURE	pag. 7

 ISTITUTO PER LO STUDIO E LA PREVENZIONE ONCOLOGICA	Procedura	Codice Aziendale CP004
	IMMUNOCITOCHIMICA	Pag. 2 di 7
	S.S. Laboratorio Regionale HPV e Biologia Molecolare	Ed. 2 Rev. 0

DISTRIBUZIONE

La presente procedura viene distribuita ai Responsabili delle seguenti Strutture, Centri di Responsabilità o Uffici che, a loro volta, provvedono a distribuirla e, ove occorra, ad illustrarla al personale interessato appartenente alla propria struttura

		Si/No
Direzione Generale		SI
Direzione Sanitaria		SI
Direzione Amministrativa		SI
Coordinamento Assistenziale e della Prevenzione		SI
Coordinamento Tecnico Sanitario		SI
Coordinamento Statistico		
S.S. Bilancio, Contabilità e Investimenti		
Ufficio Comunicazione, Attività editoriali e Pianificazione eventi scientifici		
S.S. Centro di Riabilitazione Oncologica (Ce.Ri.On)		
STRUTTURE COMPLESSE	STRUTTURE SEMPLICI COLLEGATE	
Laboratorio Regionale di Prevenzione Oncologica	Laboratorio Regionale HPV e Biologia Molecolare	SI
	Citologia Extra Screening e Sistema Qualità in Citologia	
Senologia Clinica		
Screening e Prevenzione Secondaria	Senologia di Screening	
	CRR Prevenzione Oncologica	
Epidemiologia Clinica	Infrastruttura e Coordinamento Registri	
	Valutazione Screening e Osservatorio Nazionale Screening (O.N.S.)	
Epidemiologia dei Fattori di Rischio e degli Stili di Vita	Epidemiologia dell'Ambiente e del Lavoro	
Biostatistica Applicata all'Oncologia		
Amministrazione, Gestione Risorse, Attività Tecniche e Supporto alla Ricerca		
Ufficio Relazioni con il Pubblico		

 ISTITUTO PER LO STUDIO E LA PREVENZIONE ONCOLOGICA	Procedura	Codice Aziendale CP004
	IMMUNOCITOCHIMICA	Pag. 3 di 7
	S.S. Laboratorio Regionale HPV e Biologia Molecolare	Ed. 2 Rev. 0

INTRODUZIONE

Nel Laboratorio Regionale di Prevenzione Oncologica (LRPO) si eseguono esami di immunocitochimica (ICC) su materiale citologico proveniente dalle strutture sanitarie della Regione Toscana o inviato dai medici curanti, finalizzati alla diagnosi e alla caratterizzazione delle neoplasie.

Tali esami sono indispensabili per un completamento diagnostico, per un corretto inquadramento istologico delle lesioni indifferenziate, per la valutazione dell'assetto recettoriale, dell'indice di proliferazione cellulare e di fattori prognostici. I test immunocitochimici vengono eseguiti su:

- agoaspirati mammari, polmonari, linfonodali, di organi profondi e agoaspirati NAS.
- liquidi delle cavità sierose: pleurici, ascitici, pericardici.
- citologici di broncoaspirati, lavaggi bronchiali, brushing bronchiali.

1. SCOPO

- esplicitare le modalità di prelievo, di accettazione, di esecuzione dell'esame, di refertazione e di archiviazione.
- uniformare i comportamenti del personale addetto a tali attività al fine di ottimizzare il lavoro, ridurre i rischi e rispondere ai requisiti normativi.

2. CAMPO DI APPLICAZIONE

La presente procedura si applica nell'ambito delle attività del personale del LRPO di ISPO.

3. TERMINOLOGIA E ABBREVIAZIONI

ACCE: Procedura informatica per inserimento dati anagrafici e gestione ricette

AMBU: Procedura informatica per prenotazione esami con dati anagrafici dell'utente; contiene tutti i codici relativi alle prestazioni effettuate all'interno dell'Istituto

AOUC: Azienda Ospedaliera Universitaria Careggi

CDQ: Controllo di qualità

CQI: Controllo di qualità interno

CED: Centro elaborazione dati

ICC: Esami di immunocitochimica su materiale citologico

IO: Istruzioni operative

LRPO: Laboratorio Regionale Prevenzione Oncologica

Nomenclatore tariffario regionale: E' l'atto formale nel quale sono indicate le singole prestazioni specialistiche, di diagnostica strumentale e di laboratorio erogabili dal servizio sanitario regionale in regime ambulatoriale

NUTE: Software gestionale di Archiviazione test del LRPO

POLM: Procedura informatica per inserimento degli esami di citologia polmonare

TSLB: Tecnico Sanitario di Laboratorio Biomedico.

 ISTITUTO PER LO STUDIO E LA PREVENZIONE ONCOLOGICA	Procedura	Codice Aziendale CP004
	IMMUNOCITOCHIMICA	Pag. 4 di 7
	S.S. Laboratorio Regionale HPV e Biologia Molecolare	Ed. 2 Rev. 0

4. RESPONSABILITA'

Figura che svolge l'attività Attività	Personale Segreteria del LRPO	Personale di front office	TSLB	Biologi
Accettazione amministrativa esterni		R		
Preparazione dei vetrini			R	C
Identificazione materiale e anticorpi da effettuare				R
Inserimento controlli positivi				R
Richiesta test immunocitochimici				R
Registrazione e accettazione			R	C
Esecuzione metodica immunocitochimica			R	C
Refertazione dei preparati al microscopio				R
Inserimento referti nel gestionale				R
Stampa referto				R
Archiviazione vetrini	R			C

R = Responsabile C = Coinvolto

5. DESCRIZIONE DELLE ATTIVITA'

5.1 PROVENIENZA ESAMI

L'esame ICC viene effettuato su campioni citologici inviati da strutture sanitarie pubbliche o convenzionate con ISPO oppure portati direttamente da utenti che si presentano ad ISPO con prescrizione medica.

La valutazione dell'assetto recettoriale e di fattori prognostici viene effettuata anche su preparati citologici di pazienti provenienti dagli ambulatori di ISPO.

5.2 TIPOLOGIA DI PREPARATI UTILIZZATI PER ICC

Gli esami di ICC vengono eseguiti su:

- preparati citologici da agoaspirato di qualsiasi organo (agoaspirati polmonari, mammari, linfonodali, pancreatici, epatici, renali, ecc). In questi casi si utilizzano i vetrini strisciati e colorati sui quali è stata eseguita la lettura della citologia.

 ISP ISTITUTO PER LO STUDIO E LA PREVENZIONE ONCOLOGICA	Procedura	Codice Aziendale CP004
	IMMUNOCITOCHIMICA	Pag. 5 di 7
	S.S. Laboratorio Regionale HPV e Biologia Molecolare	Ed. 2 Rev. 0

- preparati di citologia esfoliativa (broncopolmonare, cavità sierose: liquidi pleurici, ascitici, cistici, ecc). Nel caso di liquidi delle cavità sierose o dei broncoaspirati il Biologo che ha letto il caso può richiedere che vengano riallestiti 4 vetrini (vedi allegato 7.8b della procedura CP010), utilizzando il materiale residuo dalla processazione del campione.
- campione citologico colorato ed utilizzato per la diagnosi, ad esempio nel caso in cui l'esame ICC sia richiesto per un completamento diagnostico.

La determinazione dei recettori e dei fattori prognostici viene effettuata utilizzando gli stessi preparati sui quali è stata fatta la diagnosi citologica, su richiesta del medico e previa autorizzazione e liberatoria da parte della paziente (allegato 7.1), oppure su un nuovo prelievo portato direttamente dall'utente.

5.3 ACCETTAZIONE CAMPIONI

L'accettazione degli esami per gli utenti esterni che affluiscono direttamente alla nostra struttura è svolta dal personale del front-office negli orari di apertura dell'Istituto.

Le richieste mediche degli esami da eseguire sui prelievi citologici refertati e archiviati dal LRPO devono essere accettate ed inserite presso la segreteria della SC LRPO solo dopo verifica della disponibilità del materiale.

Le richieste mediche devono essere inserite nel gestionale ACCE dal personale del front-office secondo le procedure di Istituto. Il personale del front office consegna poi le richieste e il materiale biologico (se non già presente in laboratorio) in laboratorio dove viene eseguita, sul gestionale NUTE, l'accettazione amministrativa del campione e la registrazione degli esami (allegato 7.5).

L'accettazione degli esami richiesti dal dirigente biologo, ai fini del completamento diagnostico, viene eseguita direttamente dal personale TSLB in NUTE (allegato 7.5).

5.4 PROCESSAZIONE DEI TEST ICC

L'individuazione dei casi su cui eseguire test di ICC per il completamento diagnostico viene effettuata giornalmente da ciascun biologo sulla base delle istruzioni operative "Immunocitochimica automatica Ventana" (allegato 7.6)

La scelta degli anticorpi da utilizzare per ciascun caso viene fatta dal Biologo, secondo quanto riportato nel dettaglio nella IO "Scelta degli anticorpi per il completamento diagnostico" (allegato 7.3).

Il foglio di lavoro, le schede di richiesta esame compilate ed i relativi vetrini siglati vengono collocati nell'apposito contenitore nell'armadio della stanza di lettura della Citologia.

Il personale TSLB provvede all'esecuzione della metodica di immunocolorazione (allegato 7.6).

5.5 CONSEGNA IN LETTURA

Il personale TSLB consegna gli esami per la lettura al biologo che ha firmato il caso che, verificata la validità della seduta in base alla IO "Immunocitochimica automatica Ventana" (allegato 7.6), procede con la refertazione.

5.6 REFERTAZIONE

Ciascun biologo dirigente o LP abilitato alla lettura provvede alla refertazione secondo le IO "Refertazione immunocitochimica" (allegato 7.7).

I test di difficile interpretazione o discordanti vengono rivisti in lettura collegiale prima di procedere alla refertazione.

 ISTITUTO PER LO STUDIO E LA PREVENZIONE ONCOLOGICA	Procedura	Codice Aziendale CP004
	IMMUNOCITOCHIMICA	Pag. 6 di 7
	S.S. Laboratorio Regionale HPV e Biologia Molecolare	Ed. 2 Rev. 0

L'esito degli esami viene quindi riportato nelle relative schede interne e inserito da ciascun biologo nel programma NUTE del gestionale LABO.

Ciascun Biologo provvede ad abbinare la risposta dell'immunocitochimica al relativo referto citologico ed a preparare la risposta definitiva per l'invio ai reparti di provenienza, collocandola nell'apposito cestello dell'armadio apposito del LRPO.

I vetrini sui quali sono stati eseguiti i test vengono archiviati con il caso citologico relativo.

Per i referti dei recettori e dei fattori prognostici, il Biologo effettua la lettura secondo le IO "Refertazione immunocitochimica" (allegato 7.7) e la risposta viene preparata dalla Segreteria di Laboratorio (allegato 7.8).

5.7 INVIO REFERTI E ARCHIVIAZIONE VETRINI

Il personale della segreteria del laboratorio provvede all'invio delle risposte. I referti degli esami pervenuti direttamente dalle aziende Ospedaliere e Sanitarie vengono inserite in buste chiuse con specificato il reparto di provenienza e rinviati mediante il servizio giornaliero di autisti.

I referti degli utenti che hanno eseguito l'esame con richiesta medica vengono portati al front-office e ritirati dal diretto interessato o da persona delegata presentando il modulo per il ritiro dei referti (allegato 7.10).

La segreteria del LRPO provvede alla archiviazione della scheda interna di ICC in un apposito contenitore nell'armadio posto nella stanza della segreteria, insieme ad una copia della liberatoria dell'esecuzione dell'esame su materiale archiviato.

I vetrini sui quali è stato effettuato il test vengono archiviati insieme al caso citologico corrispondente e alla liberatoria.

5.8 CONTROLLI DI QUALITA'

5.8.1. Controlli di qualità interni

Vengono utilizzati campioni citologici testati precedentemente per l'anticorpo interessato. I controlli interni negativi e positivi, preparati utilizzando il materiale residuo di casi positivi, vengono strisciati dal personale TSLB su indicazione del Biologo responsabile, utilizzando il modulo apposito (allegato 8 della procedura CP010). Su ciascun vetrino viene riportato l'anticorpo da testare.

I controlli positivi e negativi così strisciati e colorati vengono riposti nelle apposite scatole nell'armadio della stanza di lettura di Citologia.

Il biologo seleziona i controlli di qualità interni che vengono inseriti in ciascuna procedura analitica di immunocitochimica e indica l'anticorpo da utilizzare (in genere viene utilizzato l'anticorpo del test numericamente più presente nella seduta).

5.8.2 Correlazione cito/immunoistochimica/istologia

Ogni 3 mesi viene eseguita una correlazione del risultato citologico/immunocitochimico con quello istologico/immunoistochimico e clinico per monitorare l'accuratezza diagnostica, consultando gli archivi ospedalieri.

5.8.3. Monitoraggio tempi di risposta

Ogni 3 mesi vengono monitorati i tempi di risposta.

 ISTITUTO PER LO STUDIO E LA PREVENZIONE ONCOLOGICA	Procedura	Codice Aziendale CP004
	IMMUNOCITOCHIMICA	Pag. 7 di 7
	S.S. Laboratorio Regionale HPV e Biologia Molecolare	Ed. 2 Rev. 0

6. RIFERIMENTI

- DPR 14.01.1997 modifiche al DL502 del 30.12.92
- LR 8 (23.02.1999)
- DCR 30 (01.02.2000)
- LR 40/2008
- LR 51 (05.08.2009)
- DPGR 61 (24.12.2010)
- DPGR 10/R del 22 marzo 2012

7. ALLEGATI

Allegato 7.1	Richiesta recettori/fattori prognostici e liberatoria
Allegato 7.2	Richiesta interna di ICC per completamento diagnostico
Allegato 7.3	IO Scelta degli anticorpi
Allegato 7.3 a	Lista anticorpi
Allegato 7.4	Foglio di lavoro
Allegato 7.5	IO Registrazione esami immunocitochimici
Allegato 7.6	IO Metodica automatica di immunocolorazione Ventana
Allegato 7.7	IO Refertazione degli esami ICC
Allegato 7.8	Risposta recettori e fattori prognostici
Allegato 7.9	Ritiro referti
Allegato 7.10	Classificazione tumori polmonari 2015

8. APPARECCHIATURE

La dotazione strumentale comprende:

- Terminale accettazione e computer
- Coloratore automatico e montatore
- Frigorifero
- Centrifuga
- Cappa aspirante
- Microscopio
- Microscopio multioculare
- Immunocoloratore Ventana
- Etichettatrice
- Coloratore Automatico e Montatore
- Penna vetrografica
- Timer
- Rack per vetrini

S.C. Laboratorio Regionale
Prevenzione Oncologica
Direttore: f.f.Dr. ssa F.Carozzi.
Tel: 055/32697852/809
Via Cosimo il Vecchio,2
50139 Firenze



Servizio
Sanitario
della
Toscana

NUMERO REGISTRO: _____

RICERCA IMMUNOCITOCHIMICA DI RECETTORI E FATTORI PROGNOSTICI

*Il presente modulo deve essere sempre accompagnato da richiesta su ricettario regionale
il ticket può essere cumulato con la citologia*

COGNOME _____ NOME _____

Data nascita _____ Cod paz. _____ Ticket _____

Tipo di materiale

- ☐ Agoaspirato mammario (2)
- ☐ Agoaspirato linfonodale (6)
- ☐ Agoaspirato polmonare (7)
- ☐ Scraping mammario (3)
- ☐

Preparato

- ☐ Fresco (1)
- ☐ Decolorato (4)
- ☐ Fissato (2)
- ☐ _____ (3)

Si richiedono i seguenti esami

- ☐ RECETTORI ER
- ☐ RECETTORI PgR
- ☐ KI 67
- ☐ C-erbB2
- ☐ _____

DATA ESAME _____

IL MEDICO _____
(sigla medico)

~~~~~  
**LA PARTE SOTTOSTANTE DEVE ESSERE COMPILATA DIRETTAMENTE DALLA  
PAZIENTE SE IL DOSAGGIO VIENE RICHiesto SUI VETRINI DELLA CITOLOGIA**

La sottoscritta \_\_\_\_\_,

nata a \_\_\_\_\_ il \_\_\_\_\_

abitante in \_\_\_\_\_ Via \_\_\_\_\_

autorizza l'utilizzo dei vetrini dell'esame citologico da lei effettuato presso Codesto Centro per il dosaggio dei recettori ormonali e dei fattori prognostici, consapevole che tali vetrini non possono essere più disponibili per eventuale consultazione

In fede \_\_\_\_\_ FIRMA \_\_\_\_\_

**MODULO INTERNO ISPO PER RICHIESTA ESAMI IMMUNOCITOCHIMICA**

**TIPO ESAME: 3**

**COGNOME** \_\_\_\_\_

**NOME** \_\_\_\_\_

**Cod. paz.** \_\_\_\_\_

**Data nascita** \_\_\_\_\_

**Data esame** \_\_\_\_\_

**CODICE PROVENIENZA**

**TIPO DI PAGAMENTO:**

**VETRINO:**

**Tipo Materiale:**

- 1) Striscio Cervico-Vaginale
- 2) Agoaspirato Mammario
- 3) Scraping ca mammario
- 4) Liquido pleurico
- 5) Liquido ascitico
- 6) Agoaspirato Linfonodale

- 7) Agoaspirato Tiroideo
- 8) Agoaspirato polmonare
- 9) Urine
- 10) Altro \_\_\_\_\_
- 11) TBNA \_\_\_\_\_
- 12) Agoaspirato \_\_\_\_\_

**Preparato**

- 1) Fissato
- 2) Colorato
- 3) Fissato e congelato
- 4) Decolorato

**STORIA CLINICA/dubbio diagnostico:**

**Biologo**

**MONOCLONALI ESEGUITI E RISULTATO**

- ☐ 27- TTF1 \_\_\_\_\_
- ☐ 44- P63 \_\_\_\_\_
- ☐ 33- CD 56 \_\_\_\_\_
- ☐ 42- CROMOGRANINA \_\_\_\_\_
- ☐ 46- NAPSINA A \_\_\_\_\_
- ☐ 45- P40\_ (SOX2) \_\_\_\_\_
- ☐ 14- EMA \_\_\_\_\_
- ☐ 11- CEA \_\_\_\_\_
- ☐ 29- CALRETININA \_\_\_\_\_
- ☐ 12- CITOCHERATINA 7 \_\_\_\_\_
- ☐ 13- CITOCHERATINA 20 \_\_\_\_\_

- ☐ 36- ER \_\_\_\_\_
- ☐ 37- PGR \_\_\_\_\_
- ☐ 40- KI-67 \_\_\_\_\_
- ☐ 39- CERB-B2 \_\_\_\_\_
- ☐ 31- CITOKA1/A3 \_\_\_\_\_
- ☐ 9- LCA \_\_\_\_\_
- ☐ 21- PSA \_\_\_\_\_
- ☐ 23- TIREOGLOBULINA \_\_\_\_\_
- ☐ 30- CA 125 \_\_\_\_\_
- ☐ 24- VIMENTINA \_\_\_\_\_
- ☐ 47- GATA3 \_\_\_\_\_
- ☐ \_\_\_\_\_

U.O Citologia Analitica e Biomolecolare

**IL BIOLOGO**

|                                                                                                                                                |                                                                          |                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------|
|  <b>ISTITUTO PER LO STUDIO<br/>E LA PREVENZIONE ONCOLOGICA</b> | Istruzione operativa                                                     | Codice Aziendale<br>CP004                                      |
|                                                                                                                                                | <b>IMMUNOCITOCHIMICA</b><br>Allegato 7.3<br>Indicazioni scelta anticorpi | <b>Pag. 1 di 5</b><br><br><b>Ed. 2 Rev 0</b><br><br>22/12/2016 |
|                                                                                                                                                | <b>S.C. LABORATORIO REGIONALE<br/>PREVENZIONE ONCOLOGICA</b>             |                                                                |

## 1. SCOPO

Non esiste alcun anticorpo capace di differenziare le cellule neoplastiche da quelle non neoplastiche e quindi è fondamentale il riconoscimento morfologico della malignità degli elementi cellulari presenti per evitare errori interpretativi.

La maggior parte dei marcatori utilizzati per la definizione diagnostica non è specifica e spesso può essere necessario utilizzare 2 o più marcatori ed interpretare i risultati alla luce del dato morfologico con molta attenzione.

## 2. CAMPO DI APPLICAZIONE

L'utilizzo delle metodiche immunocitochimiche e l'uso di anticorpi monoclonali trova la sua maggiore applicazione nella classificazione di istotipo, in particolare nelle neoplasie scarsamente differenziate e nella distinzione tra neoplasie primitive e metastatiche.

La nuova classificazione WHO del tumore polmonare del Settembre 2015 definisce le linee guida per tale utilizzo nel materiale citologico (allegato 7.10).

Un altro campo di applicazione importante riguarda la determinazione dell'assetto recettoriale e dei fattori prognostici nei tumori della mammella indispensabili, ai fini della programmazione terapeutica.

## 3. DESCRIZIONE DELL'ATTIVITA'

I test immunocitochimica vengono eseguiti sui vetrini citologici colorati.

La scelta degli anticorpi da utilizzare dipende dal dubbio diagnostico; per quanto riguarda la diagnostica polmonare deve essere fatta secondo le indicazioni della classificazione WHO 2015 su materiale citologico.

### PRINCIPALI PANEL DI ANTICORPI:

#### 1) LA TIPIZZAZIONE DEI TUMORI POLMONARI

**ADENOCARCINOMA POLMONARE:** TTF1, Napsina A, CK7

**CARCINOMA A CELLULE SQUAMOSE:** P63, P 40, citocheratina 5/6

**CARCINOMA A PICCOLE CELLULE (SCLC):** CD56, sinaptofisina

#### 2) L'IDENTIFICAZIONE DELLA NATURA DEL TUMORE PRIMITIVO

**ADENOCARCINOMA polmonare:** TTF1+, Citocheratina 7 +, Citocheratina 20-

**ADENOCARCINOMA COLON/RETTO:** Citocheratina 20+/Citocheratina 7-, TTF1-

**ADENOCARCINOMA MAMMELLA:** Citocheratina 7+, ER, PgR variabili, GATA-3+

**ADENOCARCINOMA OVAIO:** Citocheratina 7+, Ca125+

**ADENOCARCINOMA PANCREAS E VIE BILIARI:** Citocheratina 7+, CK20-

|                                                                                                                                                |                                                                          |                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------|
|  <b>ISTITUTO PER LO STUDIO<br/>E LA PREVENZIONE ONCOLOGICA</b> | Istruzione operativa                                                     | Codice Aziendale<br>CP004                                      |
|                                                                                                                                                | <b>IMMUNOCITOCHIMICA</b><br>Allegato 7.3<br>Indicazioni scelta anticorpi | <b>Pag. 1 di 5</b><br><br><b>Ed. 2 Rev 0</b><br><br>22/12/2016 |
|                                                                                                                                                | <b>S.C. LABORATORIO REGIONALE<br/>PREVENZIONE ONCOLOGICA</b>             |                                                                |

**CARCINOMA RENALE A CELLULE CHIARE:** Citocheratina AE1/AE3 +, vimentina +

**ADENOCARCINOMA VESCICA:** Citocheratina 7+, Citocheratina 20+, Citocheratina 5-6+

**MELANOMA:** S100+, HMB-45+

**ADENOCARCINOMA PROSTATA:** PSA+, Citocheratina AE1/AE3+,

**CARCINOMA A PICCOLE CELLULE (SCLC):** CD56+, Cromogranina A+, NSE+

### 3) FATTORI PROGNOSTICI MAMMELLA

RECETTORE PER L'ESTROGENO

RECETTORE PER IL PROGESTERONE

INDICE PROLIFERATIVO (KI-67)

c-erb B2

### PRINCIPALI DUBBI DIAGNOSTICI

Vengono di seguito elencati le diagnosi differenziali che più frequentemente richiedono l'utilizzo di anticorpi monoclonali.

Se il materiale citologico è scarso si testeranno prima gli anticorpi più idonei a risolvere il dubbio e via via gli altri del panel consigliato.

**A) DIAGNOSI DIFFERENZIALE FRA ADENOCARCINOMA PRIMITIVO POLMONARE O METASTASI DA CARCINOMA DELLA MAMMELLA: TTF1, RECETTORE PER L'ESTROGENO (ER), RECETTORE PER IL PROGESTERONE (PGR), GATA-3.**

- TTF1 +: adenocarcinoma primitivo polmonare.
- TTF1 -, GATA-3+: compatibile con un'origine mammaria.
- TTF1 -, Er +, Pgr +, compatibile con metastasi da carcinoma della mammella.
- TTF1 -, Pgr -, Er -/+ : si può solo ipotizzare un'origine mammaria, ma questa non è da considerarsi certa, anche se Er è positivo, perché la sola positività dell'ER non è dirimente, vista l'evidenza scientifica che gli adenocarcinoma polmonari possono esprimere il recettore estrogenico.

|                                                                                                                                                |                                                                          |                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------|
|  <b>ISTITUTO PER LO STUDIO<br/>E LA PREVENZIONE ONCOLOGICA</b> | Istruzione operativa                                                     | Codice Aziendale<br>CP004                                      |
|                                                                                                                                                | <b>IMMUNOCITOCHIMICA</b><br>Allegato 7.3<br>Indicazioni scelta anticorpi | <b>Pag. 1 di 5</b><br><br><b>Ed. 2 Rev 0</b><br><br>22/12/2016 |
|                                                                                                                                                | <b>S.C. LABORATORIO REGIONALE<br/>PREVENZIONE ONCOLOGICA</b>             |                                                                |

**B) DIAGNOSI DIFFERENZIALE FRA ADENOCARCINOMA PRIMITIVO POLMONARE E METASTASI DA ADENOCARCINOMA DI ORIGINE INTESTINALE: TTF1, CITOCHERATINA 20, CITOCHERATINA 7**

- TTF1+, Citocheratina 20-: primitivo polmonare
- TTF1-, Citocheratina 20+: metastasi da adenocarcinoma di origine intestinale
- TTF1-, Citocheratina 20+, Citocheratina 7-: metastasi da adenocarcinoma di origine intestinale
- TTF1-, Citocheratina 20-, Citocheratina 7+: probabile adenocarcinoma primitivo polmonare

**C) DIAGNOSI DIFFERENZIALE FRA NEOPLASIA INDIFFERENZIATA, DUBBIA SE CARCINOMA A PICCOLE CELLULE (SCLC) O CARCINOMA NON PICCOLE CELLULE (NSCLC): CD56, P63, P40, TTF1**

- CD56 +, P63- o P40-: SCLC
- CD56+, TTF1+/ -: SCLC
- CD56 -, P63+ o P40+: NSCLC, riferibile a carcinoma squamoso
- CD56-, P63- o P40-, TTF1+: NSCLC, riferibile ad adenocarcinoma

**D) DIAGNOSI DIFFERENZIALE FRA SCLC E LINFOMA/LINFOCITI: CD56, LCA, TTF1**

- CD56 +/LCA-: carcinoma a piccole cellule
- CD56-/ LCA +: linfoma /linfociti

**E) DIAGNOSI DIFFERENZIALE FRA METASTASI DA NEOPLASIA EPITELIALE E LINFOMA: CITOCHERATINA AE1/AE3, LCA**

- citocheratina AE1/AE3+/LCA-: metastasi epiteliale
- LCA+/citocheratina AE1/AE3-: linfoma

|                                                                                                                                        |                                                                   |                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------------|
|  ISTITUTO PER LO STUDIO<br>E LA PREVENZIONE ONCOLOGICA | Istruzione operativa                                              | Codice Aziendale<br>CP004                                      |
|                                                                                                                                        | IMMUNOCITOCHIMICA<br>Allegato 7.3<br>Indicazioni scelta anticorpi | <b>Pag. 1 di 5</b><br><br><b>Ed. 2 Rev 0</b><br><br>22/12/2016 |
|                                                                                                                                        | S.C. LABORATORIO REGIONALE<br>PREVENZIONE ONCOLOGICA              |                                                                |

**PRINCIPALI PROBLEMATICHE DI DIAGNOSI DIFFERENZIALE NEI VERSAMENTI DELLE CAVITÀ SIEROSE, principalmente su liquidi pleurici ed ascitici**

**1) IPERPLASIA REATTIVA O METASTASI EPITELIALE (in particolare adenocarcinoma)**

1. Il pannello consigliato è: **EMA, Calretinina**,  
EMA+, Calretinina-: adenocarcinoma

**2) POSITIVO, dubbio se MESOTELIOMA o ADENOCARCINOMA**

Il pannello consigliato può variare in base alla sospettata sede di origine dell'adenocarcinoma.

Se il sospetto è di un adenocarcinoma polmonare il pannello consigliato comprende: **Calretinina, EMA e TTF1**

EMA-/ + di membrana, TTF1-, Calretinina + depone per mesotelioma

EMA+, TTF1+/-, Calretinina – depone per un adenocarcinoma

Se la sede sospettata dell'Adenocarcinoma è extrapolmonare le indicazioni per la scelta del pannello sono quelle elencate al punto 2 per l'identificazione della natura del tumore primitivo.

**Attenzione all'utilizzo ed all'interpretazione delle citocheratine che sono positive anche nelle cellule mesoteliali normali e/o reattive e quindi devono essere utilizzate solo su campioni sicuramente positivi per cellule neoplastiche.**

**LISTA ANTICORPI UTILIZZATI CON APPARECCHIO AUTOMATICO**  
**VENTANA**

| Anticorpo        | CLONE        | DITTA   |
|------------------|--------------|---------|
| CA-125           | OC125        | VENTANA |
| Calretinin       | POLICLONALE  | VENTANA |
| CD56             | 123C3        | VENTANA |
| CEA              | CEA31        | VENTANA |
| ANTI-CHROMO      | LK2H10       | VENTANA |
| anti-Ck20        | SP33         | VENTANA |
| anti-CK7         | SP52         | VENTANA |
| anti-EMA         | E29          | VENTANA |
| ER               | SP1          | VENTANA |
| Ki-67            | 30-9         | VENTANA |
| ANTI-LCA(CD45)   | RP2/18       | VENTANA |
| anti-P63         | 4A4          | VENTANA |
| ANTI-PAN KERATIN | AE1+AE3+CK26 | VENTANA |
| PATHWAY HER2     | 4B5          | VENTANA |
| anti-PR          | 1E2          | VENTANA |

|             |             |         |
|-------------|-------------|---------|
| ANTI-PSA    | POLICLONALE | VENTANA |
| S100        | 4C4.9       | VENTANA |
| P40 (SOX-2) | SP76        | VENTANA |
| anti-TTF-1  | 8G7G3/1     | VENTANA |
| Vimentin    | V9          | VENTANA |
| GATA3       | L50-823     | VENTANA |

DATA ICC: \_\_\_\_\_ OPERATORE: \_\_\_\_\_ VETRINI SEDUTA: \_\_\_\_\_

| N.ro vetrino              | Paziente: | N.ro registro             | Tot. vetrini: |
|---------------------------|-----------|---------------------------|---------------|
| ANTICORPI MONOCLONALI:    |           |                           |               |
| 1. _____ H2O _____ Xilolo |           | 4. _____ H2O _____ Xilolo |               |
| 2. _____ H2O _____ Xilolo |           | 5. _____ H2O _____ Xilolo |               |
| 3. _____ H2O _____ Xilolo |           | 6. _____ H2O _____ Xilolo |               |
| OSSERVAZIONI: _____       |           |                           |               |

| N.vetrino                 | Nome: | N.ro registro             | Tot vetrini: |
|---------------------------|-------|---------------------------|--------------|
| ANTICORPI MONOCLONALI:    |       |                           |              |
| 1. _____ H2O _____ Xilolo |       | 4. _____ H2O _____ Xilolo |              |
| 2. _____ H2O _____ Xilolo |       | 5. _____ H2O _____ Xilolo |              |
| 3. _____ H2O _____ Xilolo |       | 6. _____ H2O _____ Xilolo |              |
| OSSERVAZIONI: _____       |       |                           |              |

| N.vetrino                 | Nome: | N.ro registro             | Tot vetrini: |
|---------------------------|-------|---------------------------|--------------|
| ANTICORPI MONOCLONALI:    |       |                           |              |
| 1. _____ H2O _____ Xilolo |       | 4. _____ H2O _____ Xilolo |              |
| 2. _____ H2O _____ Xilolo |       | 5. _____ H2O _____ Xilolo |              |
| 3. _____ H2O _____ Xilolo |       | 6. _____ H2O _____ Xilolo |              |
| OSSERVAZIONI: _____       |       |                           |              |

| N.vetrino                 | Nome: | N.ro registro             | Tot vetrini: |
|---------------------------|-------|---------------------------|--------------|
| ANTICORPI MONOCLONALI:    |       |                           |              |
| 1. _____ H2O _____ Xilolo |       | 4. _____ H2O _____ Xilolo |              |
| 2. _____ H2O _____ Xilolo |       | 5. _____ H2O _____ Xilolo |              |
| 3. _____ H2O _____ Xilolo |       | 6. _____ H2O _____ Xilolo |              |
| OSSERVAZIONI: _____       |       |                           |              |

| N.vetrino                 | Nome: | N.ro registro             | Tot vetrini: |
|---------------------------|-------|---------------------------|--------------|
| ANTICORPI MONOCLONALI:    |       |                           |              |
| 1. _____ H2O _____ Xilolo |       | 4. _____ H2O _____ Xilolo |              |
| 2. _____ H2O _____ Xilolo |       | 5. _____ H2O _____ Xilolo |              |
| 3. _____ H2O _____ Xilolo |       | 6. _____ H2O _____ Xilolo |              |
| OSSERVAZIONI: _____       |       |                           |              |

|                                                                                                                                                |                                                                                                     |                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
|  <b>ISTITUTO PER LO STUDIO<br/>E LA PREVENZIONE ONCOLOGICA</b> | <b>ISTRUZIONE OPERATIVA</b>                                                                         | <b>Codice Aziendale</b><br>CP004                                      |
|                                                                                                                                                | <b>IMMUNOCITOCHIMICA</b><br>Allegato 7.5<br><b>REGISTRAZIONE<br/>ESAMI DI<br/>IMMUNOCITOCHIMICA</b> | <b>Pag. 1 di 2</b><br><br><b>Edizione 2</b><br><br><b>Revisione 0</b> |
|                                                                                                                                                | <b>S.C. LABORATORIO REGIONALE<br/>PREVENZIONE ONCOLOGICA</b>                                        |                                                                       |

Gruppo di redazione: Cristina Maddau, Francesca Carozzi

### 1. SCOPO

Esplicitare le modalità di registrazione degli esami di immunocitochimica.

### 2. CAMPO DI APPLICAZIONE

La presente I.O. si applica nell'ambito delle attività del personale del LRPO del di ISPO, che esegue i test di immunocitochimica.

### 3. DESCRIZIONE DELL'ATTIVITA'

La registrazione dell'esame immunocitochimico viene fatta dal personale tecnico del laboratorio (TSLB) nel programma NUTE del LABO per gli esami richiesti per il completamento diagnostico e dal personale della segreteria amministrativa per le richieste su ricettario regionale proveniente dai medici esterni, situato al primo piano del LRPO.

Gli esami immunocitochimici per completamento diagnostico su campioni citologici che sono già stati accettati sul programma POLM del gestionale LABO, vengono richiesti dal biologo/lettore tramite l'apposito modulo (allegato 7.2).

#### 3.1 ACCETTAZIONE ESAME ICC

Al momento dell'esecuzione del test, il personale TSLB:

- entra con il proprio codice e password nel gestionale LABO
- seleziona la voce "8" NUOVE TECNOLOGIE
- ricerca paziente per CODICE  
(se richiesto inserire il consenso al trattamento dei dati con una X)

cliccare F5 e inserire:

- data esame: data accettazione
- tipo esame: "3" per ICC, "1" per recettori
- mittente: codice indicato sul modulo interno di richiesta
- sigla: lasciare vuoto
- numero registro: "X"
- preparato: riportare il codice barrato nell'apposito riquadro "preparato" a destra del modulo interno ISPO (allegato 9.2)

|                                                                                                                                                |                                                                                                                 |                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
|  <b>ISTITUTO PER LO STUDIO<br/>E LA PREVENZIONE ONCOLOGICA</b> | <b>ISTRUZIONE OPERATIVA</b>                                                                                     | <b>Codice Aziendale</b><br>CP004                                      |
|                                                                                                                                                | <b>IMMUNOCITOCHIMICA</b><br>Allegato 7.5<br><b>REGISTRAZIONE</b><br><b>ESAMI DI</b><br><b>IMMUNOCITOCHIMICA</b> | <b>Pag. 2 di 2</b><br><br><b>Edizione 2</b><br><br><b>Revisione 0</b> |
|                                                                                                                                                | <b>S.C. LABORATORIO REGIONALE<br/>PREVENZIONE ONCOLOGICA</b>                                                    |                                                                       |

- tipo materiale: codice indicato sul modulo interno di richiesta (per la TBNA usare il codice 10)
- numero del vetrino: indicato sul modulo interno di richiesta
- biologo: codice del biologo indicato sul modulo interno di richiesta
- invio

Compare una nuova schermata con tutti i dati inseriti precedentemente e con i campi da completare con :

- il codice “esame” indicato sul modulo interno di richiesta (es. 27-TTF1)
- esito: “8”(esame da completare)
- il centro di costo: indicato sul modulo interno di richiesta alla voce “tipo di pagamento”.

Nota: i campioni con codice pagamento 01/011 (richiesta regionale proveniente da OSMA) sono da inserire con il codice 08/07

### 3.2 ACCETTAZIONE RECETTORI

- Le richieste di recettori ormonali e di fattori prognostici, pre-accettate dal personale front-office, vengono registrate dal personale dell'accettazione amministrativa su un apposito registro cartaceo, situato nella stanza della segreteria del LRPO, con una numerazione progressiva preceduta dalla W e con la trascrizione manuale di tutti i dati identificativi del paziente, degli esami richiesti presenti nella scheda di richiesta interna (allegato 9.1). Il personale della segreteria provvede alla ricerca del preparato citologico e lo consegna insieme a tutta la documentazione al Biologo incaricato che dovrà scegliere i vetrini adeguati per eseguire il test.

|                                                                                                                                                |                                                                                             |                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------|
|  <b>ISTITUTO PER LO STUDIO<br/>E LA PREVENZIONE ONCOLOGICA</b> | Istruzione operativa                                                                        | Codice Aziendale<br>CP004                               |
|                                                                                                                                                | <b>IMMUNOCITOCHIMICA</b><br>Allegato 7.6<br><b>IMMUNOCITOCHIMICA<br/>AUTOMATICA VENTANA</b> | <b>Pag. 1 di 6</b><br><b>Ed. 2 Rev. 0</b><br>22/12/2016 |
|                                                                                                                                                | S.C. LABORATORIO REGIONALE<br>PREVENZIONE ONCOLOGICA                                        |                                                         |

**Gruppo di Redazione:** Cristina Maddau, Francesca Carozzi, Paola Cifarelli

## 1. SCOPO

Effettuazione automatica metodica immunocitochimica.

## 2. CAMPO DI APPLICAZIONE

Viene effettuata su campioni citologici colorati.

## 3. DESCRIZIONE DELL'ATTIVITA'

La procedura immunocitochimica comprende le seguenti fasi:

1. Scelta ed identificazione dei vetrini su cui eseguire i test
2. Preprazione lista di lavoro per la seduta di ICC
3. Pretrattamento dei vetrini per la seduta ICC
4. Smontaggio e re-idratazione dei vetrini
5. Immunocolorazione su coloratore automatico BENCHMARK GX
6. Montaggio manuale dei vetrini con coprioggetto.

### 3.1 SCELTA ED IDENTIFICAZIONE DEI VETRINI SU CUI ESEGUIRE I TEST

Giornalmente, per ciascun caso con richiesta medica o per i casi per i quali ICC è eseguita per completamento diagnostico, il Biologo:

- compila il modulo di richiesta per gli esami immunocitochimici (allegato 9.2).
- identifica i vetrini su cui eseguire i test di ICC sia con la matita che con la penna vetrografica specificando l'anticorpo da testare, il numero di vetrino e, se necessario, segna con la vetrografica, sul lato del vetrino opposto al coprioggetto, le zone di interesse con i punti più rappresentativi e più ricchi di materiale.
- colloca la scheda compilata e relativi vetrini siglati nell'apposito contenitore nell'armadio della stanza di lettura della Citologia (Maddau-Matucci).

### 3.2 PREPARAZIONE LISTA DI LAVORO PER LA SEDUTA ICC

Per ogni seduta ICC deve essere preparato un foglio di lavoro (allegato 9.4) dove sono riportati i casi da testare presenti nell'apposito contenitore posto nell'armadio della stanza xxxxx e i vetrini di controllo da inserire nella sessione.

La lista di lavoro viene predisposta dal Biologo (di solito il pomeriggio antecedente) e per ciascun caso viene riportato:

il nome del paziente, il numero del vetrino e la lista degli anticorpi da eseguire.

|                                                                                                                                                |                                                                              |                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|---------------------------------------------------------|
|  <b>ISTITUTO PER LO STUDIO<br/>E LA PREVENZIONE ONCOLOGICA</b> | Istruzione operativa                                                         | Codice Aziendale<br>CP004                               |
|                                                                                                                                                | IMMUNOCITOCHIMICA<br>Allegato 7.6<br>IMMUNOCITOCHIMICA<br>AUTOMATICA VENTANA | <b>Pag. 2 di 6</b><br><b>Ed. 2 Rev. 0</b><br>22/12/2016 |
|                                                                                                                                                | S.C. LABORATORIO REGIONALE<br>PREVENZIONE ONCOLOGICA                         |                                                         |

### 3.3. PRETRATTAMENTO DEI VETRINI PER LA SEDUTA ICC

I vetrini presenti nella lista di cui al punto 3.2, vengono collocati dal Dirigente negli appositi cestelli di plastica da 20 controllando che tutti siano siglati con la penna vetrografica e rispettando l'ordine presente nel foglio di lavoro.

Il primo vetrino del cestello deve essere il controllo positivo della reazione.

Almeno il giorno antecedente all'esecuzione dell'immunocolorazione, i vetrini devono essere immersi in xilolo/H<sub>2</sub>O sotto la cappa chimica aspirante del LRPO, nella stanza colorazione citologia ("Laboratorio Citologia Vaginale ed Extravaginale 1"), per consentire la rimozione del vetrino copri oggetto.

I vetrini montati con montante non acquoso (attualmente Ecomount) vengono posti in xilolo overnight; il tempo di rimozione del vetrino copri oggetto è variabile in base alla data di apposizione del copri oggetto (da 30' a 6 ore circa).

I vetrini montati con montante acquoso vengono posti in H<sub>2</sub>O tiepida overnight; il tempo di rimozione del vetrino copri oggetto è variabile in base alla data di apposizione del copri oggetto (da 30' a 2 ore circa).

Il foglio di lavoro e le schede di richiesta degli esami vengono posizionate sul bancone di lavoro accanto alla medesima cappa, in una cestellina identifica con 'Seduta ICC'.

### 3.4 SMONTAGGIO E RE-IDRATAZIONE DEI VETRINI

Il giorno in cui viene eseguito il test ICC, il TSLB provvede alla rimozione del vetrino coprioggetto dai casi da processare; tale operazione viene eseguita manualmente nella stanza 'CITOLOGIA COLORAZIONE' ("Laboratorio Citologie Vaginali ed Extravaginali 1") sotto la cappa CHIMICA aspirante, se necessario con l'aiuto di un bisturi/pinzetta.

Si procede, sempre sotto cappa aspirante, ad eseguire i passaggi per la reidratazione dei vetrini:

- 10' in xilolo
- 5' in una miscela 50:50 di xilolo-etanolo assoluto
- 5' in etanolo assoluto per due volte
- 5' in etanolo 95%
- 5' in etanolo 80%
- 5' in etanolo 70%
- 5' in etanolo 50%
- 5' in H<sub>2</sub>O distillata

### 3.5 IMMUNOCOLORAZIONE SU COLORATORE AUTOMATICO BENCHMARK GX

Il sistema di processazione automatica per ICC è collocato nella stanza 'Citologia Extravaginali' ("Laboratorio HPV 1").

Il "Sistema di immunocolorazione automatizzato" (Benchmark GX, Ventana) costituito da:

- personal computer con il software specifico

|                                                                                                                                        |                                                                                  |                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------|
|  ISTITUTO PER LO STUDIO<br>E LA PREVENZIONE ONCOLOGICA | Istruzione operativa                                                             | Codice Aziendale<br>CP004                                       |
|                                                                                                                                        | IMMUNOCITOCHIMICA<br>Allegato 7.6<br><br>IMMUNOCITOCHIMICA<br>AUTOMATICA VENTANA | <b>Pag. 3 di 6</b><br><br><b>Ed. 2 Rev. 0</b><br><br>22/12/2016 |
|                                                                                                                                        | S.C. LABORATORIO REGIONALE<br>PREVENZIONE ONCOLOGICA                             |                                                                 |

- immunocoloratore con il modulo di colorazione e il modulo della fluidica
- etichettatrice per la stampa delle etichette
- stampante per la stampa del report relativo alla seduta.

**Per avviare la corsa sullo strumento BENCHMARK GX è necessario effettuare i seguenti passaggi:**

- accendere il coloratore, se spento, premendo il pulsante posizionato dietro il modulo di colorazione in basso a dx (la spia POWER ON diventa verde)
- accendere il personal computer e dal desktop selezionare con doppio click l'icona "VENTANA"; si apre la finestra principale del programma e si accende una spia verde alla voce "CONNESSO"
- cliccare sulla voce "Protocolli" posta a destra della schermata iniziale
- selezionare "Creare o modificare protocolli", quindi assicurarsi che alla voce "Procedure" sia selezionato "BMX Ultra View DAB Par"; altrimenti selezionarlo
- cliccare sull'icona raffigurante un "BARECODE/ETICHETTA" dalla sbarra strumenti in basso
- cliccare su "PROTOCOLLI"
- da "Selezionare il formato" scegliere ISPO
- scegliere, nel riquadro "Selezionare i protocolli Bnechmark", l'anticorpo da testare con un doppio click (ad ogni anticorpo è associato uno specifico protocollo di colorazione); l'anticorpo selezionato compare nella colonna di destra

NOTA: Se si hanno esami in doppio per lo stesso anticorpo:

- Scrivere, su "Copie", il numero di etichette da creare per l'anticorpo in questione
  - Cliccare "Aggiungi" e l'elenco delle etichette da creare compare nella colonna di destra;
- cliccare "Chiudi/Stampa"

-compare una schermata con riportato:

Cod Paziente: inserite il nome e cognome del paziente

N° Vetrino: inserire il numero vetrino

-cliccare "Stampare"

-attaccare le etichette sui vetrini precedentemente smontati e reidratati: questa fase è cruciale per la corretta identificazione del caso, quindi occorre che il tslb verifichi con attenzione controllando dal foglio di lavoro.

|                                                                                                                                        |                                                                                  |                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------|
|  ISTITUTO PER LO STUDIO<br>E LA PREVENZIONE ONCOLOGICA | Istruzione operativa                                                             | Codice Aziendale<br>CP004                                       |
|                                                                                                                                        | IMMUNOCITOCHIMICA<br>Allegato 7.6<br><br>IMMUNOCITOCHIMICA<br>AUTOMATICA VENTANA | <b>Pag. 4 di 6</b><br><br><b>Ed. 2 Rev. 0</b><br><br>22/12/2016 |
|                                                                                                                                        | S.C. LABORATORIO REGIONALE<br>PREVENZIONE ONCOLOGICA                             |                                                                 |

-Prendere i dispenser:

-del “Kit Detection” rispettando l’ordine con cui si trovano nel kit (il dispensatore del DAB e dell’H<sub>2</sub>O<sub>2</sub> devono essere vicini);

-degli anticorpi previsti per la seduta

-dell’Hematossilina per la contro colorazione

-montare tutto sull’apposito carosello.

ATTENZIONE! togliere i tappi da ogni dispensatore prima di posizionarlo sul carosello

-Posizionare il carosello sul rotore del modulo di colorazione assicurandosi che sia perfettamente incastrato sul perno centrale del rotore

-Controllare i livelli delle taniche con le soluzioni tampone posizionate nel modulo dei fluidi; è sufficiente che i contenitori siano riempiti fino a metà; non è necessario sostituire i fluidi già bordo, ma è possibile aggiungere ai fluidi già presenti i volumi preparati ex novo: lo strumento utilizza LCS pronto all’uso, Ez Prep e Reaction Buffer da diluire 1 :10 con acqua distillata; richiede, comunque, la presenza a bordo di tutti i fluidi

NOTA: E’ necessario registrare qualsiasi reagente o consumabile nuovo

-cliccare “Registrare”

-cliccare “Registrare Prodotti Ventana”

-leggere il chip di registrazione presente sulla confezione o sulla tanica utilizzando la pennetta apposita posta sul monitor del computer, tenendo a contatto la pennetta sul chip finchè non compare OK

-verificare cmq manualmente scadenze dei reagenti e anticorpi

-controllare la tanica di scarico; e se necessario svuotarla nell’apposita tanica per i rifiuti liquidi a rischio chimico (C.E.R 180/106)

-aprire il coperchio del modulo di colorazione

-posizionare i vetrini (massimo 20) con l’etichetta verso l’alto e verso l’operatore, verificando che siano ben alloggiati nelle postazioni dei vetrini

-chiudere il coperchio

-posizionare il carosello

-cliccare “Avviare la seduta”

|                                                                                                                                        |                                                                                  |                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------|
|  ISTITUTO PER LO STUDIO<br>E LA PREVENZIONE ONCOLOGICA | Istruzione operativa                                                             | Codice Aziendale<br>CP004                                       |
|                                                                                                                                        | IMMUNOCITOCHIMICA<br>Allegato 7.6<br><br>IMMUNOCITOCHIMICA<br>AUTOMATICA VENTANA | <b>Pag. 5 di 6</b><br><br><b>Ed. 2 Rev. 0</b><br><br>22/12/2016 |
|                                                                                                                                        | S.C. LABORATORIO REGIONALE<br>PREVENZIONE ONCOLOGICA                             |                                                                 |

-fleggare nella schermata le voci evidenziate: carosello posizionato, tappi rimossi e inserire il numero di vetrini da colorare

-cliccare OK alla finestra che compare dopo l'avvio, con l'avviso della rilevazione della scarsa quantità di alcuni reagenti

-attendere davanti allo strumento la corretta lettura di tutte le etichette dei vetrini e i barcode dei reagenti. Il coloratore legge prima i barcode dei vetrini; se li ha letti tutti, tutte le posizioni sono colorate in verde; se qualche barcode non è stato letto segnala con un allarme sonoro la mancata lettura e lascia in bianco la posizione mancante; in quest'ultimo caso:

-silenziare l'allarme

-aprire lo sportellino del modulo di colorazione e assicurarsi che il vetrino e l'etichetta del barcode siano correttamente posizionate

-chiudere lo sportellino

-cliccare la voce "RIPROVARE"

Il coloratore dopo la lettura dei barcode dei vetrini legge i barcode dei dispensatori dei reattivi/anticorpi; se tutti i reagenti /anticorpi necessari al protocollo e alla metodica selezionata sono presenti, passa direttamente alla loro processazione segnalando il "Tempo" necessario alla fine della corsa, altrimenti segnala tutto quello che manca o è incompatibile con il programma, nel riquadro della videata; in quest'ultima circostanza:

-selezionare la voce "ANNULLARE"

-provvedere a caricare quanto richiesto

-cliccare "AVVIARE LA CORSA".

Durante la corsa il personale TLSB inserisce al computer nel programma NUTE del gestionale LABO le richieste degli esami in base alle IO (allegato 9.5).

-al termine della corsa, appare in rosso il messaggio "Corsa completata" (lo strumento emette anche un segnale sonoro); cliccare sull'icona gialla "Block Notes"

-controllare che la corsa è andata a buon fine

|                                                                                                                                        |                                                                                  |                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------|
|  ISTITUTO PER LO STUDIO<br>E LA PREVENZIONE ONCOLOGICA | Istruzione operativa                                                             | Codice Aziendale<br>CP004                                       |
|                                                                                                                                        | IMMUNOCITOCHIMICA<br>Allegato 7.6<br><br>IMMUNOCITOCHIMICA<br>AUTOMATICA VENTANA | <b>Pag. 6 di 6</b><br><br><b>Ed. 2 Rev. 0</b><br><br>22/12/2016 |
|                                                                                                                                        | S.C. LABORATORIO REGIONALE<br>PREVENZIONE ONCOLOGICA                             |                                                                 |

-cliccando su “Stampare”, quindi “Stampare i rapporti delle corse” è possibile vedere e stampare il report della corsa

-togliere il carosello con i dispenser

-aprire il coperchio del modulo di colorazione, togliere i vetrini e posizionarli nell'apposito porta vetrini di plastica da 20

-selezionare l'icona “PULIRE”, dalla barra strumenti in basso: l'operazione richiede 10 minuti

**ATTENZIONE:** E' fondamentale eseguire la pulizia della macchina alla fine di ogni seduta

-infine per chiudere il programma “Ventana”, cliccare sull'icona “Uscire”

-appare una finestra in cui viene chiesto di fare il backup, cliccare sì

-spegnere il personal computer (importante per salvaguardare i file del data base)

-togliere i dispensatori reagenti/anticorpi dal carosello, tapparli e conservarli in frigo (n.3 stanza 41B)

-controllare che la corsa sia andata a buon fine.

### 3.6 MONTAGGIO MANUALE DEI VETRINI

A fine corsa, lavare i vetrini per 5' con soluzione di acqua corrente e detergente per eliminare il tampone oleoso. Proseguire il lavaggio con acqua corrente tiepida; successivamente montare i vetrini con coprioggetti 24x50mm utilizzando 2-3 gocce di montante acquoso.

I vetrini montati vengono posizionati su un vassoio e abbinati per paziente; insieme ai moduli interni di richiesta ed alla lista di lavoro vengono dati in lettura ai Biologi di riferimento per la refertazione (allegato 9.7).

|                                                                                                                                        |                                                      |                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|--------------------------------------------------|
|  ISTITUTO PER LO STUDIO<br>E LA PREVENZIONE ONCOLOGICA | ISTRUZIONE OPERATIVA                                 | Codice Aziendale<br>CP004                        |
|                                                                                                                                        | IMMUNOCITOCHIMICA<br>Allegato 7.7<br>REFERTAZIONE    | Pag. 1 di 2<br><br>Edizione 2<br><br>Revisione 0 |
|                                                                                                                                        | S.C. LABORATORIO REGIONALE<br>PREVENZIONE ONCOLOGICA |                                                  |

**Gruppo di redazione:** Cristina Maddau, Francesca Carozzi

## 1. SCOPO

Descrivere il processo di refertazione degli esami immunocitochimici e fattori prognostici eseguiti su preparati citologici. Soltanto i Dirigenti Biologi e LP autorizzati dal Direttore di SC possono refertare queste tipologie di esami.

La valutazione del preparato deve essere preceduta dalla verifica dei controlli interni di seduta.

## 2. CAMPO DI APPLICAZIONE

La refertazione immunocitochimica riguarda i recettori ormonali ed i fattori prognostici su agoaspirati mammari e linfonodali, gli anticorpi applicati per il completamento diagnostico di preparati citologici di diverse sedi anatomiche, in particolare citologici polmonari.

## 3. DESCRIZIONE DELL'ATTIVITA'

I preparati di immunocitochimica vengono refertati dal Biologo che ha in lettura il caso e l'interpretazione del test viene riportata sulla richiesta cartacea dell'esame. L'esito del test ICC viene inserita giornalmente direttamente dal Biologo nel programma NUTE, prima dell'invio della risposta ai reparti o al paziente.

### REFERTAZIONE IMMUNOCITOCHIMICA DI RECETTORI ORMONALI E FATTORI PROGNOSTICI

La refertazione comprende le seguenti valutazioni:

- **1. NEGATIVO:** assenza di immunocolorazione o colorazione al di sotto del CUT-OFF
- **4. POSITIVO:** presenza di immunocolorazione sulle cellule diagnostiche
- **5. NON VALUTABILE:** scarsa cellularità o altre cause.

**Recettore per l'estrogeno e per il progesterone:** la positività è nucleare e vengono contate le cellule positive rispetto alle negative, riportando la positività in percentuale (devono essere contate un minimo di 200 cellule).

**Ki-67:** la positività è nucleare e vengono contate le cellule positive rispetto alle negative e si riporta la positività in percentuale.

Indichiamo in tutti i casi la percentuale di positività ottenuta, anche se il dato è significativo solo quando è maggiore del 10%. È consigliabile contare almeno 250 cellule.

|                                                                                                                                        |                                                      |                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|--------------------------------------------------|
|  ISTITUTO PER LO STUDIO<br>E LA PREVENZIONE ONCOLOGICA | ISTRUZIONE OPERATIVA                                 | Codice Aziendale<br>CP004                        |
|                                                                                                                                        | IMMUNOCITOCHIMICA<br>Allegato 7.7<br>REFERTAZIONE    | Pag. 2 di 2<br><br>Edizione 2<br><br>Revisione 0 |
|                                                                                                                                        | S.C. LABORATORIO REGIONALE<br>PREVENZIONE ONCOLOGICA |                                                  |

### **C-erb-B2:** positività membranaria

Si esprime un valore quantitativo, ma anche qualitativo. La positività deve essere membranaria o membrano-citoplasmatica e non solo citoplasmatica.

I casi con positività membranaria non completa o con bassa percentuale di positività vengono refertati come debolmente positivi.

### **REFERTAZIONE IMMUNOCITOCHIMICA DI ANTICORPI AI FINI DEL COMPLETAMNETO DIAGNOSTICO.**

L'interpretazione del risultato deve essere fatta alla luce dell'esame citologico e del dubbio diagnostico. E' infatti fondamentale identificare il tipo di cellule in cui è presente l'immunocolorazione per una corretta interpretazione dell'esame.

La refertazione comprende le seguenti valutazioni:

- **4. POSITIVO:** l'esame immunocitochimico è da considerarsi positivo quando è presente una colorazione citoplasmatica o nucleare a carico delle cellule morfologicamente alterate e supposte neoplastiche. La colorazione positiva di elementi non significativi, quali elementi flogistici o altro non deve essere considerata ai fini della valutazione del dato immunocitochimica.
- **1. NEGATIVO:** l'esame è considerato negativo se è assente l'immunocolorazione a carico delle cellule morfologicamente alterate e sospette neoplastiche. La colorazione positiva di elementi non significativi, quali elementi flogistici o altro, non deve essere valutata come positiva.
- **5. NON VALUTABILE:** l'esame non è considerato adeguato quando non si ritrovano gli elementi cellulari che erano stati identificati nel preparato citologico e/o quando il preparato è degenerato o le cellule non visibili per la flogosi.

S.C. Laboratorio Regionale  
Prevenzione Oncologica  
Direttore: f.f.Dr. ssa F. Carozzi.  
Tel: 055/32697852/809  
Via Cosimo il Vecchio, 2  
50139 Firenze

Numero Registro \_\_\_\_\_

COGNOME \_\_\_\_\_ NOME \_\_\_\_\_

Cod. Paz. \_\_\_\_\_ Data nascita \_\_\_\_\_ Data esame \_\_\_\_\_

Mittente \_\_\_\_\_

|                                                      |                                                    |
|------------------------------------------------------|----------------------------------------------------|
| <input type="checkbox"/> 1 Striscio Cervico-Vaginale | <input type="checkbox"/> 6 Agoaspirato linfonodale |
| <input type="checkbox"/> 2 Agoaspirato Mammario      | <input type="checkbox"/> 7 Agoaspirato Tiroideo    |
| <input type="checkbox"/> 3 Scraping ca mammario      | <input type="checkbox"/> 8 Agoaspirato polmonare   |
| <input type="checkbox"/> 4 Liquido pleurico          | <input type="checkbox"/> 9 Urine                   |
| <input type="checkbox"/> 5 Liquido ascitico          | <input checked="" type="checkbox"/> Altro _____    |

| Preparato                             |                     |
|---------------------------------------|---------------------|
| <input type="checkbox"/> 1            | Fissato             |
| <input type="checkbox"/> 2            | Fissato e colorato  |
| <input type="checkbox"/> 3            | Fissato e congelato |
| <input checked="" type="checkbox"/> X | Decolorato          |

### RISULTATO ICC

☒ Nome anticorpo \_\_\_\_\_  
☒ Nome anticorpo \_\_\_\_\_

NOTE \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

IL BIOLOGO

Proc CP004

## INFORMAZIONI RIGUARDANTI LA CONSEGNA DEI REFERTI O RISULTATI CLINICI (DATI SENSIBILI D.Lgs. 196/2003, art.84)

In ottemperanza a quanto disposto dalla legge sui dati sensibili, i risultati degli esami ambulatoriali o certificazioni sanitarie in genere, confezionati in buste chiuse, **possono essere rilasciati solo a:**

- **diretti interessati o, in caso di minori, a chi ne esercita la potestà genitoriale;**
- **persona munita di consenso scritto (delega) rilasciato dal titolare del referto o dagli aventi diritto.**

Si ricorda che le persone munite di delega, oltre ad essere identificate con un documento, devono esibire, insieme alla delega, anche un documento identificativo del delegante.

**Il recapito a domicilio dei referti**, per motivate esigenze e su espressa richiesta dell'utente, può avvenire, in via del tutto eccezionale, dopo l'accertamento del pagamento del ticket e con l'addebito delle spese postali solo per i residenti fuori della Regione Toscana.

**La consegna dei referti** deve avvenire nel luogo ed in orari indicati nel **MODULO** stampato in questo foglio debitamente compilato, rilasciato dall'Istituto.

**I referti pronti NON ritirati entro 30 giorni dalla data della consegna perdono il beneficio del ticket. L'Amministrazione addebiterà il costo totale (Legge 412/91, art. 4, comma 18).**

**Il personale non è autorizzato a fornire informazioni telefoniche sull'esito degli esami.**

### SCHEMA GUIDA PER IL RITIRO DEI REFERTI

| Per l'utente<br>che ritira il referto    | Per l'utente<br>Condizioni per la consegna<br>del referto                                                                                                                                                                                                                                                                                                    | Per l'operatore<br>Procedura d'identificazione<br>dell'utente                                                                                                             |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Persona intestataria del referto</b>  | <ol style="list-style-type: none"> <li>1 presentazione del Modulo debitamente compilato;</li> <li>2 presentazione del documento di identificazione;</li> <li>3 presentazione della ricevuta del pagamento del ticket, se dovuto</li> </ol>                                                                                                                   | Identificazione dell'utente con annotazione dei dati del documento:<br><b>tipo</b> di documento<br><b>numero</b> del documento<br><b>data ed Ente</b> che l'ha rilasciato |
| <b>Persona con Delega</b>                | Stessa procedura dei punti 1, 2, 3, e presentazione della <b>delega</b> rilasciata dal delegante con un documento identificativo dello stesso                                                                                                                                                                                                                | Stessa procedura di identificazione dell'utente e poi allegare alla richiesta medica la <b>delega</b>                                                                     |
| <b>Tutore legale<br/>(art. 414 C.C.)</b> | <ol style="list-style-type: none"> <li>1 presentazione del Modulo debitamente compilato;</li> <li>2 presentazione del documento di identificazione;</li> <li>3 presentazione della ricevuta del pagamento del ticket, se dovuto;</li> <li>4 presentazione del documento probatorio del proprio diritto (atti rilasciati dalle autorità pubbliche)</li> </ol> | Stessa procedura di identificazione dell'utente e poi allegare copia fotostatica del documento probatorio dello stato di diritto                                          |
| <b>Curatore<br/>(art. 415 C.C.)</b>      | Stessa procedura                                                                                                                                                                                                                                                                                                                                             | Stessa procedura                                                                                                                                                          |

# The 2015 World Health Organization Classification of Lung Tumors

## Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification

William D. Travis, MD,\* Elisabeth Brambilla, MD,† Andrew G. Nicholson, MD,‡ Yasushi Yatabe, MD,§ John H. M. Austin, MD,|| Mary Beth Beasley, MD,¶ Lucian R. Chirieac, MD,# Sanja Dacic, MD,\*\* Edwina Duhig, MD,†† Douglas B. Flieder, MD,‡‡ Kim Geisinger, MD,§§ Fred R. Hirsch, MD,|| Yuichi Ishikawa, MD,¶¶ Keith M. Kerr, MD,## Masayuki Noguchi, MD,\*\*\* Giuseppe Pelosi, MD,††† Charles A. Powell, MD,‡‡‡ Ming Sound Tsao, MD,§§§ and Ignacio Wistuba, MD,||| ||  
On Behalf of the WHO Panel

**Abstract:** The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes from the 2004 WHO classification. The most significant changes in this edition involve (1) use of immunohistochemistry throughout the classification, (2) a new emphasis on genetic studies, in particular, integration of molecular testing to help personalize treatment strategies for advanced lung cancer patients, (3) a new classification for small biopsies and cytology

similar to that proposed in the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, (4) a completely different approach to lung adenocarcinoma as proposed by the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, (5) restricting the diagnosis of large cell carcinoma only to resected tumors that lack any clear morphologic or immunohistochemical differentiation with reclassification of the remaining former large cell carcinoma subtypes into different categories, (6) reclassifying squamous cell carcinomas into keratinizing, nonkeratinizing, and basaloid subtypes with the nonkeratinizing tumors requiring immunohistochemistry proof of squamous differentiation, (7) grouping of neuroendocrine tumors together in one category, (8) adding *NUT* carcinoma, (9) changing the term sclerosing hemangioma to sclerosing pneumocytoma, (10) changing the name hamartoma to "pulmonary hamartoma," (11) creating a group of PEComatous tumors that include (a) lymphangioleiomyomatosis, (b) PEComa, benign (with clear cell tumor as a variant) and (c) PEComa, malignant, (12) introducing the entity pulmonary myxoid sarcoma with an *EWSR1-CREB1* translocation, (13) adding the entities myoepithelioma and myoepithelial carcinomas, which can show *EWSR1* gene rearrangements, (14) recognition of usefulness of *WWTR1-CAMTA1* fusions in diagnosis of epithelioid hemangioendotheliomas, (15) adding Erdheim-Chester disease to the lymphoproliferative tumor, and (16) a group of tumors of ectopic origin to include germ cell tumors, intrapulmonary thymoma, melanoma and meningioma.

**Key Words:** WHO classification, Lung tumors, Lung cancer, Lung adenocarcinoma, Squamous cell carcinoma, Small cell carcinoma, Large cell carcinoma, Carcinoid.

(*J Thorac Oncol.* 2015;10: 1243–1260)

\*Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; †Dept d'Anatomie et Cytologie Pathologiques, CHU Albert Michallon, University Joseph Fourier; INSERM U823 Institut Albert Bonniot, Grenoble, France; ‡Department of Pathology, Royal Brompton Hospital, London, United Kingdom; §Department of Pathology, Aichi Cancer Center, Nagoya, Japan; ||Department of Radiology, Columbia University Medical Center, New York, New York; ¶Department of Pathology, Ichan School of Medicine at Mt Sinai, New York, New York; #Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; \*\*Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania; ††Sullivan Nicolaides Pathology, The John Flynn Hospital, Tugun, Queensland, Australia; ‡‡Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; §§Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi; |||University of Colorado Cancer Center UCHSC, Aurora, Colorado; ¶¶Department of Pathology, The JFCR Cancer Institute, Tokyo, Japan; ##Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom; \*\*\*Department of Pathology; Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba, Japan; †††Department of Pathology and Laboratory Medicine, Istituto Nazionale Tumori, Milan, Italy; ‡‡‡Division of Pulmonary Critical Care and Sleep Medicine, Ichan School of Medicine at Mt Siai, New York, New York; §§§Department of Pathology, Princess Margaret Hospital, Toronto, Canada; and ||||Department of Pathology, MD Anderson Cancer Center, Houston, Texas.

Disclosure: The authors declare no conflict of interest.

Address for correspondence: William D. Travis, MD, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065. E-mail: travisw@mskcc.org

DOI: 10.1097/JTO.0000000000000630

Copyright © 2015 by the International Association for the Study of Lung Cancer

ISSN: 1556-0864/15/1009-1243

The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published (Table 1).<sup>1</sup> This follows previous WHO

TABLE 1. 2015 WHO Classification of Lung Tumors<sup>a,b,c</sup>

| Histologic Type and Subtypes                                 | ICDO Code           |
|--------------------------------------------------------------|---------------------|
| <b>Epithelial tumors</b>                                     |                     |
| Adenocarcinoma                                               | 8140/3              |
| Lepidic adenocarcinoma <sup>a</sup>                          | 8250/3 <sup>d</sup> |
| Acinar adenocarcinoma                                        | 8551/3 <sup>d</sup> |
| Papillary adenocarcinoma                                     | 8260/3              |
| Micropapillary adenocarcinoma <sup>a</sup>                   | 8265/3              |
| Solid adenocarcinoma                                         | 8230/3              |
| Invasive mucinous adenocarcinoma <sup>a</sup>                | 8253/3 <sup>d</sup> |
| Mixed invasive mucinous and nonmucinous adenocarcinoma       | 8254/3 <sup>d</sup> |
| Colloid adenocarcinoma                                       | 8480/3              |
| Fetal adenocarcinoma                                         | 8333/3              |
| Enteric adenocarcinoma <sup>a</sup>                          | 8144/3              |
| Minimally invasive adenocarcinoma <sup>a</sup>               |                     |
| Nonmucinous                                                  | 8256/3 <sup>d</sup> |
| Mucinous                                                     | 8257/3 <sup>d</sup> |
| Preinvasive lesions                                          |                     |
| Atypical adenomatous hyperplasia                             | 8250/0 <sup>d</sup> |
| Adenocarcinoma in situ <sup>a</sup>                          |                     |
| Nonmucinous                                                  | 8250/2 <sup>d</sup> |
| Mucinous                                                     | 8253/2 <sup>d</sup> |
| Squamous cell carcinoma                                      | 8070/3              |
| Keratinizing squamous cell carcinoma <sup>a</sup>            | 8071/3              |
| Nonkeratinizing squamous cell carcinoma <sup>a</sup>         | 8072/3              |
| Basaloid squamous cell carcinoma <sup>a</sup>                | 8083/3              |
| Preinvasive lesion                                           |                     |
| Squamous cell carcinoma in situ                              | 8070/2              |
| <b>Neuroendocrine tumors</b>                                 |                     |
| Small cell carcinoma                                         | 8041/3              |
| Combined small cell carcinoma                                | 8045/3              |
| Large cell neuroendocrine carcinoma                          | 8013/3              |
| Combined large cell neuroendocrine carcinoma                 | 8013/3              |
| <b>Carcinoid tumors</b>                                      |                     |
| Typical carcinoid tumor                                      | 8240/3              |
| Atypical carcinoid tumor                                     | 8249/3              |
| <b>Preinvasive lesion</b>                                    |                     |
| Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia | 8040/0 <sup>d</sup> |
| Large cell carcinoma                                         | 8012/3              |
| Adenosquamous carcinoma                                      | 8560/3              |
| <b>Sarcomatoid carcinomas</b>                                |                     |
| Pleomorphic carcinoma                                        | 8022/3              |
| Spindle cell carcinoma                                       | 8032/3              |
| Giant cell carcinoma                                         | 8031/3              |
| Carcinosarcoma                                               | 8980/3              |
| Pulmonary blastoma                                           | 8972/3              |
| <b>Other and Unclassified carcinomas</b>                     |                     |
| Lymphoepithelioma-like carcinoma                             | 8082/3              |
| NUT carcinoma <sup>a</sup>                                   | 8023/3 <sup>d</sup> |
| <b>Salivary gland-type tumors</b>                            |                     |
| Mucoepidermoid carcinoma                                     | 8430/3              |
| Adenoid cystic carcinoma                                     | 8200/3              |
| Epithelial-myoepithelial carcinoma                           | 8562/3              |
| Pleomorphic adenoma                                          | 8940/0              |

(Continued)

TABLE 1. (Continued)

| Histologic Type and Subtypes                                                            | ICDO Code           |
|-----------------------------------------------------------------------------------------|---------------------|
| <b>Papillomas</b>                                                                       |                     |
| Squamous cell papilloma                                                                 | 8052/0              |
| Exophytic                                                                               | 8052/0              |
| Inverted                                                                                | 8053/0              |
| Glandular papilloma                                                                     | 8260/0              |
| Mixed squamous and glandular papilloma                                                  | 8560/0              |
| <b>Adenomas</b>                                                                         |                     |
| Sclerosing pneumocytoma <sup>a</sup>                                                    | 8832/0              |
| Alveolar adenoma                                                                        | 8251/0              |
| Papillary adenoma                                                                       | 8260/0              |
| Mucinous cystadenoma                                                                    | 8470/0              |
| Mucous gland adenoma                                                                    | 8480/0              |
| <b>Mesenchymal tumors</b>                                                               |                     |
| Pulmonary hamartoma                                                                     | 8992/0 <sup>d</sup> |
| Chondroma                                                                               | 9220/0              |
| <b>PEComatous tumors<sup>a</sup></b>                                                    |                     |
| Lymphangioliomyomatosis                                                                 | 9174/1              |
| PEComa, benign <sup>a</sup>                                                             | 8714/0              |
| Clear cell tumor                                                                        | 8005/0              |
| PEComa, malignant <sup>a</sup>                                                          | 8714/3              |
| Congenital peribronchial myofibroblastic tumor                                          | 8827/1              |
| Diffuse pulmonary lymphangiomatosis                                                     |                     |
| Inflammatory myofibroblastic tumor                                                      | 8825/1              |
| Epithelioid hemangioendothelioma                                                        | 9133/3              |
| Pleuropulmonary blastoma                                                                | 8973/3              |
| Synovial sarcoma                                                                        | 9040/3              |
| Pulmonary artery intimal sarcoma                                                        | 9137/3              |
| Pulmonary myxoid sarcoma with <i>EWSR1-CREB1</i> translocation <sup>a</sup>             | 8842/3 <sup>d</sup> |
| <b>Myoepithelial tumors<sup>a</sup></b>                                                 |                     |
| Myoepithelioma                                                                          | 8982/0              |
| Myoepithelial carcinoma                                                                 | 8982/3              |
| <b>Lymphohistiocytic tumors</b>                                                         |                     |
| Extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma) | 9699/3              |
| Diffuse large cell lymphoma                                                             | 9680/3              |
| Lymphomatoid granulomatosis                                                             | 9766/1              |
| Intravascular large B cell lymphoma <sup>a</sup>                                        | 9712/3              |
| Pulmonary Langerhans cell histiocytosis                                                 | 9751/1              |
| Erdheim-Chester disease                                                                 | 9750/1              |
| <b>Tumors of ectopic origin</b>                                                         |                     |
| <b>Germ cell tumors</b>                                                                 |                     |
| Teratoma, mature                                                                        | 9080/0              |
| Teratoma, immature                                                                      | 9080/1              |
| Intrapulmonary thymoma                                                                  | 8580/3              |
| Melanoma                                                                                | 8270/3              |
| Meningioma, NOS                                                                         | 9530/0              |
| <b>Metastatic tumors</b>                                                                |                     |

<sup>a</sup>The morphology codes are from the ICDO.<sup>2</sup> Behavior is coded /0 for benign tumors, /1 for unspecified, borderline or uncertain behavior, /2 for carcinoma in situ and grade III intraepithelial neoplasia, and /3 for malignant tumors.

<sup>b</sup>The classification is modified from the previous WHO classification<sup>1</sup> taking into account changes in our understanding of these lesions.

<sup>c</sup>This table is reproduced from the 2015 WHO Classification by Travis et al.<sup>1</sup>

<sup>d</sup>These new codes were approved by the International Agency on Cancer Research/WHO Committee for ICDO.

<sup>e</sup>New terms changed or entities added since 2004 WHO Classification.<sup>1</sup>

LCNEC, large cell neuroendocrine carcinoma, WHO, World Health Organization; ICDO International Classification of Diseases for Oncology.

Classifications of Lung Tumors in 1967 and 1981, of Lung and Pleural Tumors in 1999 and Tumors of the Lung, Pleura, Thymus and Heart in 2004.<sup>3-6</sup> Due in part to remarkable advances in lung cancer genetics and therapy in the past decade, there are significant changes since the 2004 WHO classification that will be summarized in this review.<sup>3</sup> Compared with the 2004 WHO Classification, there are multiple major changes for the common lung cancers most of which follow the 2011 lung adenocarcinoma classification sponsored by the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS), which has essentially been adopted with only minor changes.<sup>7</sup> The most significant changes in this edition compared with 2004 involve (1) use of immunohistochemistry throughout the classification including for resected lung cancers, (2) a new emphasis on genetic studies, in particular integration of molecular testing to help personalize treatment strategies for advanced lung cancer patients, (3) a new classification for small biopsies and cytology as proposed by the 2011 IASLC/ATS/ERS Classification with a different approach to classification of resected lung cancers, (4) a completely different approach to lung adenocarcinoma as proposed by the 2011 IASLC/ATS/ERS Classification, (5) restricting the diagnosis of large cell carcinoma only to resected tumors that lack any clear morphologic or immunohistochemical differentiation with reclassification of the remaining former large cell carcinoma subtypes into different categories, (6) reclassifying squamous cell carcinomas into keratinizing, nonkeratinizing and basaloid subtypes with the nonkeratinizing tumors requiring immunohistochemistry proof of squamous differentiation, (7) grouping of neuroendocrine tumors together in one category, (8) adding nuclear protein in testis (NUT) carcinoma to a category of other and unclassified tumors, (9) changing the term sclerosing hemangioma to sclerosing pneumocytoma and moving this tumor to the adenoma category, (10) changing the name hamartoma to "pulmonary hamartoma," (11) creating a group of PEComatous tumors that include (a) lymphangioleiomyomatosis (LAM), (b) PEComa, benign (with clear cell tumor as a variant), and (c) PEComa, malignant, (12) introducing the entity pulmonary myxoid sarcoma with an *EWSR1-CREB1* translocation, (13) adding the entities myoepithelioma and myoepithelial carcinomas which can show *EWSR1* gene rearrangements, (14) recognition of usefulness of *WWTR1-CAMTA1* fusions in diagnosis of epithelioid hemangioendotheliomas (15) adding Erdheim-Chester disease to the lymphoproliferative tumors,<sup>1</sup> and (16) a new group of tumors of ectopic origin was created to include germ cell tumors, intrapulmonary thymoma, melanoma and meningioma.

Much of the work of this classification was accomplished through the Pathology Committee of the IASLC, who supported annual meetings of the committee over the past decade and an international multidisciplinary meeting in December of 2014 in New York. This included meetings of the IASLC/ATS/ERS lung adenocarcinoma classification between 2008 and 2010 in which major changes were based on a systematic review of the literature and consensus majority votes of the international multidisciplinary panel. For the WHO Book, lead authors were assigned to the major subchapter topics, and they coordinated the development of consensus and the writing assignments among the assigned coauthors.

In addition, all significant changes from the 2004 book were discussed and approved by majority voting during a consensus meeting sponsored by the WHO and International Agency on Cancer Research in Lyon, France in April of 2014.

### MORE EXPANDED USE OF IMMUNOHISTOCHEMISTRY

In prior WHO classifications lung cancer diagnosis was based mainly on light microscopy using routine hematoxylin and eosin and sometimes mucin stained slides. Immunohistochemistry was introduced for the first time in the 1999 WHO Classification and, even in the 2004 WHO classification, immunohistochemistry for lung cancer diagnosis was limited to large cell neuroendocrine carcinomas (LCNEC), sarcomatoid carcinomas, and carcinomas in the differential diagnosis with malignant mesothelioma.<sup>3,6</sup> However, throughout the 2015 WHO Classification, immunohistochemistry is now recommended, when possible, not only for small biopsies/cytology, but also for resected specimens in certain settings such as solid adenocarcinoma, nonkeratinizing squamous cell carcinoma, large cell carcinoma, neuroendocrine tumors, and sarcomatoid carcinomas. With certain drugs approved for specific subgroups of non-small cell lung cancers (NSCLC) patients (i.e., bevacizumab, pemetrexed for nonsquamous histologies), the requirement for more exact histopathological subtyping is mandatory. Whenever immunohistochemistry is used in diagnosis, care must be taken to ensure high-quality staining and participation in a quality assurance program is recommended. Furthermore, care must be taken in the use of different antibody clones and in the interpretation of different degrees of staining.

### NEW IMPORTANCE OF HISTOLOGY AND GENETICS FOR PERSONALIZED MEDICINE IN ADVANCED LUNG CANCER

One of the great advances in the past decade in lung cancer diagnosis and treatment is the concept of personalized medicine, where therapeutic decisions are based on the specific histologic and genetic characteristics of the patient's tumor. This has given a new importance for pathologists to classify NSCLC further into specific pathologic subtypes (e.g., adenocarcinoma versus squamous cell carcinoma) as this determines eligibility for certain types of molecular testing and therapeutic strategies. Until the past decade, there have been no therapeutic implications to classify the NSCLC tumors further, so little attention was given to the distinction of adenocarcinoma and squamous cell carcinoma in small tissue samples. This situation changed dramatically with the discovery of several therapeutic options that are only approved for treatment of patients with specific histologic types. Discovery that epidermal growth factor (*EGFR*) mutations and anaplastic lymphoma kinase (*ALK*) rearrangements are effective targets for *EGFR* tyrosine kinase inhibitors or *ALK* inhibitors in patients with advanced lung adenocarcinoma has not only revolutionized therapeutic strategies, but transformed clinical practice for pathologists.<sup>7</sup> The new imperative for pathologists to distinguish between squamous cell carcinoma and adenocarcinoma was further emphasized by the observation that *EGFR* mutations and rearrangements of *ALK* and *ROS1* are found primarily in adenocarcinoma,

that pemetrexed is effective in patients with advanced lung adenocarcinoma rather than squamous cell carcinoma, and that bevacizumab is contraindicated in patients with squamous cell carcinoma, whereas Nivolumab (a programmed death-ligand [PDL] antibody) was most recently approved by the U.S. Food and Drug Agency in patients with advanced lung squamous cell carcinoma.<sup>7,8</sup> Because of the therapeutic implications, molecular testing for *EGFR* mutation and *ALK* rearrangement is today recommended by multiple leading clinical and pathology societies in tumors classified as adenocarcinoma and in cases where an adenocarcinoma component cannot be excluded.<sup>7,9,10</sup>

## LUNG CANCER DIAGNOSIS IN SMALL BIOPSIES AND CYTOLOGY SPECIMENS

New criteria for the diagnosis of lung cancer based on small biopsies and cytology are proposed in the 2015 WHO classification. These guidelines are important because two thirds of lung cancer patients are presenting in advanced stages, and their diagnosis is usually established based on small biopsy and cytology specimens.<sup>7</sup> Furthermore, it might be anticipated with the introduction of lung cancer screening that more patients, also in early stages of the disease, will be diagnosed based on small specimens. Furthermore, these specimens are needed not only for an accurate pathologic classification, but these small tissue samples also need to be managed carefully

for molecular testing.<sup>7,9,10</sup> This is the first WHO classification to provide standardized criteria and terminology for lung cancer diagnosis in small biopsies (bronchoscopic, needle, or core biopsies) and cytology (Tables 2 and 3).<sup>7</sup> The previous 1967, 1981, 1999, and 2004 WHO classifications addressed lung cancer classification based primarily on resection specimens.<sup>3–6</sup> Cytology was included for the first time in the 2004 WHO Classification; however, practical issues of diagnosing lung cancer in small biopsies were not addressed.<sup>3</sup> Furthermore, because there was no clinical need to classify NSCLC further, the diagnosis of NSCLC without further specification was encouraged to avoid discrepancies with subsequent resected specimens. In small biopsies, the percentage of NSCLC cases diagnosed as not otherwise specified (NOS) has been as high as 30% to 50%, and recent data from the Surveillance Epidemiology and End Results registry suggests the frequency of this NOS diagnosis has been increasing over time.<sup>12–15</sup> Until now, there have been no established standardized criteria or terminology for the diagnosis of lung cancer in small biopsies or cytology. However, over recent years, the situation has changed dramatically because of the major therapeutic implications of accurate histologic diagnosis and the need for molecular testing for eligibility to specific therapies. For this reason, it is recommended to reduce use of the term NSCLC NOS as much as possible and classify tumors according to their specific histologic subtype.<sup>7,11</sup>

**TABLE 2.** Terminology and Criteria for Adenocarcinoma, Squamous Cell Carcinoma, and NSCC NOS in Small Biopsies and Cytology Compared with Terms in Resection Specimens<sup>a</sup>

| New Small Biopsy/Cytology Terminology                                                                                                       | Morphology/Stains                                                                                      | 2015 WHO Classification in Resection Specimens                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Adenocarcinoma (describe identifiable patterns present)                                                                                     | Morphologic adenocarcinoma patterns clearly present                                                    | Adenocarcinoma predominant pattern: lepidic, acinar, papillary, solid, and micropapillary                         |
| Adenocarcinoma with lepidic pattern (if pure, add note: an invasive component cannot be excluded)                                           |                                                                                                        | Minimally invasive adenocarcinoma, adenocarcinoma in situ, or an invasive adenocarcinoma with a lepidic component |
| Invasive mucinous adenocarcinoma (describe patterns present; use term mucinous adenocarcinoma with lepidic pattern if pure lepidic pattern) |                                                                                                        | Invasive mucinous adenocarcinoma                                                                                  |
| Adenocarcinoma with colloid features                                                                                                        |                                                                                                        | Colloid adenocarcinoma                                                                                            |
| Adenocarcinoma with fetal features                                                                                                          |                                                                                                        | Fetal adenocarcinoma                                                                                              |
| Adenocarcinoma with enteric features <sup>b</sup>                                                                                           |                                                                                                        | Enteric adenocarcinoma                                                                                            |
| NSCC, favor adenocarcinoma <sup>c</sup>                                                                                                     | Morphologic adenocarcinoma patterns not present but supported by special stains (i.e., TTF-1 positive) | Adenocarcinoma (solid pattern may be just one component of the tumor)                                             |
| Squamous cell carcinoma                                                                                                                     | Morphologic squamous cell patterns clearly present                                                     | Squamous cell carcinoma                                                                                           |
| NSCC, favor squamous cell carcinoma <sup>c</sup>                                                                                            | Morphologic squamous cell patterns not present but supported by stains (i.e., p40-positive)            | Squamous cell carcinoma (nonkeratinizing pattern may be a component of the tumor)                                 |
| NSCC NOS <sup>d</sup>                                                                                                                       | No clear adenocarcinoma, squamous or neuroendocrine morphology or staining pattern                     | Large cell carcinoma                                                                                              |

<sup>a</sup>Modified from the articles by Travis et al.<sup>1,2,11</sup>

<sup>b</sup>Metastasis of colorectal cancer should be carefully excluded with judicious immunohistochemical stains and clinical evaluation.

<sup>c</sup>These categories do not always correspond to solid adenocarcinoma or nonkeratinizing squamous cell carcinoma, respectively. Poorly differentiated components in adenocarcinoma or squamous cell carcinoma may be sampled.

<sup>d</sup>NSCC NOS pattern can be seen not only in large cell carcinomas but also when the solid poorly differentiated component of adenocarcinomas or squamous cell carcinomas is sampled but does not express immunohistochemical markers or mucin

NSCC, non-small cell carcinoma; NOS, not otherwise specified; TTF, thyroid transcription factor; WHO, World Health Organization.

**TABLE 3.** Diagnostic Terminology for Small Biopsy/Cytology Compared with the 2015 WHO Terms in Resection Specimens with Small Cell Carcinoma, LCNEC, Adenosquamous Carcinoma, and Sarcomatoid Carcinoma<sup>a</sup>

| Small Biopsy/Cytology Terminology/Criteria                                                                                                                                                                                                                                                    | 2015 WHO Classification in Resections                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Small cell carcinoma                                                                                                                                                                                                                                                                          | Small cell carcinoma                                                                                                               |
| NSCC with NE morphology and positive NE markers, possible LCNEC                                                                                                                                                                                                                               | LCNEC                                                                                                                              |
| NSCC with NE morphology<br>If negative NE markers comment: This is a NSCC where LCNEC is suspected, but stains failed to demonstrate NE differentiation.                                                                                                                                      | Large cell carcinoma with NE morphology (LCNEM)                                                                                    |
| Morphologic squamous cell and adenocarcinoma patterns present; NSCC, NOS<br>Comment that adenocarcinoma and squamous components are present and this could represent adenosquamous carcinoma.                                                                                                 | Adenosquamous carcinoma (if both components $\geq 10\%$ )                                                                          |
| Morphologic squamous cell or adenocarcinoma patterns not present but immunostains favor separate glandular and adenocarcinoma components: NSCC, NOS<br>Specify the results of the immunohistochemical stains and the interpretation and comment this could represent adenosquamous carcinoma. | Adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma or large cell carcinoma with unclear immunohistochemical features |
| NSCC with spindle cell and/or giant cell carcinoma (mention if adenocarcinoma or squamous carcinoma are present)                                                                                                                                                                              | Pleomorphic, spindle cell, and/or giant cell carcinoma                                                                             |

<sup>a</sup>Modified from the articles by Travis et al.<sup>1,7,11</sup>

LCNEC, large cell neuroendocrine carcinoma; NOS, not otherwise specified; NSCC, non-small cell carcinoma; NE, neuroendocrine; WHO, World Health Organization.

The specifics of the lung cancer classification in small biopsies and cytology are explained in more detail elsewhere.<sup>7,11</sup> Briefly, tumors that have clear morphologic patterns of adenocarcinoma (acinar, papillary, lepidic, micropapillary) or squamous cell carcinoma (unequivocal keratinization and well formed classical bridges) can be diagnosed as adenocarcinoma or squamous cell carcinoma, respectively, without immunohistochemistry, unless a pneumocyte marker such as thyroid transcription factor (TTF)-1 is desired to address primary versus metastatic adenocarcinoma (Table 2). However, in the setting of poorly differentiated tumors that do not show clear differentiation by routine microscopy, a limited immunohistochemical workup is recommended to allow for an accurate diagnosis and also to preserve as much tissue for molecular testing as possible. Most tumors can be classified using a single adenocarcinoma marker (e.g., TTF-1 or mucin) and a single squamous marker (e.g., p40 or p63). Non-small cell carcinomas (NSCC, without the L for lung) that show no clear adenocarcinoma or squamous cell carcinoma morphology or immunohistochemical markers are regarded as NSCC not otherwise specified (NOS). In this setting, it is recommended that pathologists use the term NSCC rather than NSCLC, because the lack of pneumocyte marker expression in small biopsies or cytology leaves open the possibility of a metastatic carcinoma and the determination of a lung primary must be established clinically after excluding other primary sites. If tumor with this morphology stains with pneumocyte markers (i.e., TTF-1), it is classified as NSCC, favor adenocarcinoma, and if it stains only with squamous markers (i.e., p40), it is classified as NSCC, favor squamous cell carcinoma (Table 2). In this way, application of immunohistochemistry increases the refinement of diagnosis so that a diagnosis of NSCC NOS can be avoided in up to 90% of cases.<sup>13,14</sup> In cases that meet criteria for NSCC NOS, consideration should be given for using

a limited immunohistochemical panel to confirming a carcinoma (e.g., cytokeratin versus S100 or CD45) or a metastasis (estrogen receptor, prostate specific antigen, paired box 8). Terminology to be used in small biopsies for other major categories of lung cancer is summarized in Table 3.<sup>7,11</sup>

It is recognized that not all laboratories worldwide will have access to immunohistochemistry, or even a mucin stain, and in this setting, the diagnosis of NSCC NOS may remain frequent. However, the current classification still needs to encompass scientific advances where they can impact patient care. Accepted markers for identification of differentiation toward adenocarcinoma are TTF-1<sup>13,14,16</sup> and Napsin-A,<sup>17</sup> both of which are approximately 80% sensitive, although TTF-1 is easier to assess as a nuclear stain. In relation to squamous differentiation, P40 is reported as the most specific and sensitive squamous marker.<sup>18–20</sup> Other previously recommended antibodies include cytokeratin 5/6 and P63.<sup>13,14</sup> A reasonable recommendation is that, when immunohistochemistry is deemed necessary, at least one antibody each for squamous and glandular differentiation, but no more than two antibodies, should be used for an initial workup in each case (e.g., TTF-1 and P40 or P63).<sup>11,21</sup> Thus a simple panel of TTF-1 and p40 may be able to classify most NSCC NOS cases. If these stains are negative, further evaluation to confirm a diagnosis of carcinoma and to exclude a metastasis is appropriate. If TTF-1 reactivity is present in one population of tumor cells and another population is positive for squamous markers, this may raise the possibility of adenosquamous carcinoma, although this diagnosis can only be made based on a resection specimen.

### Need to Apply New WHO Criteria in Future Clinical Trials and Genetic Studies

There is a great need for these new terminology and diagnostic criteria for small biopsies and cytology to be

applied in clinical trials of patients with advanced lung cancers.<sup>22</sup> Unfortunately, most of the existing clinical trial data regarding histology are based on studies where some cases would be reclassified if this new approach were applied. For example, some of the data regarding pemetrexed efficacy in cancers other than squamous cell carcinoma and regarding the toxicity of bevacizumab in squamous cell carcinomas need to be reevaluated with the new criteria.

In addition, future large-scale genetic studies such as The Cancer Genome Atlas need to incorporate the new criteria for both small biopsies and resection specimens, which now require immunohistochemistry to precisely classify poorly differentiated tumors such as solid adenocarcinoma or nonkeratinizing squamous cell carcinoma.<sup>1</sup> This was not possible with the recent lung squamous cell carcinoma and adenocarcinoma The Cancer Genome Atlas projects,<sup>23,24</sup> but, fortunately, this was done with the Clinical Lung Cancer Genome Project, which allowed for precise classification of the tumors that resulted in critical genetic data to guide some of the key revisions in the current WHO Classification, particularly for large cell carcinoma.<sup>25</sup>

### Histologic Grading of Lung Cancer

There is no established histologic grading system for most lung cancers. Some tumors such as neuroendocrine tumors are inherently graded as they are classified with low-grade typical carcinoid, intermediate-grade atypical carcinoid, and high-grade LCNEC and small cell carcinoma. Other tumors such as large cell carcinoma and pleomorphic carcinoma are always high grade. In resection specimens, proposals have been made for grading lung adenocarcinoma using architectural versus nuclear approaches or a combination of both.<sup>26-30</sup> At the moment, grading according to the single most predominant pattern appears to be a simple and sufficient approach. Most studies show lepidic adenocarcinomas are low grade; acinar and papillary tumors are intermediate grade; solid and micropapillary tumors are high grade.<sup>31,32</sup> However, it would be useful to stratify further the intermediate-grade acinar and papillary adenocarcinomas, and this may be a good role for nuclear grading and mitotic counts.<sup>27-29,33,34</sup> However, more investigation is needed to address which approach is clinically relevant. For resected squamous cell carcinomas, there is very little data available, but nuclear diameter has been shown to be an independent predictor of worse outcome.<sup>35</sup> In one cytologic study, nuclear grading provided prognostic distinctions in aspiration biopsies.<sup>36</sup> Tumor budding has been recently reported to be an independent prognostic factor in both lung adenocarcinoma and squamous cell carcinoma.<sup>35,37-39</sup> In conclusion, there is a great need for additional studies of histological grading in lung cancer.

### LUNG CANCER CLASSIFICATION IN RESECTION SPECIMENS

The remainder of this discussion regarding lung cancer primarily addresses diagnosis and classification in resection specimens. In some of these tumors such as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA), large cell carcinoma, adenosquamous carcinoma, and pleomorphic carcinoma, the diagnosis cannot be made without complete evaluation of the entire tumor histologically.

## ADENOCARCINOMA

### Major Changes in Adenocarcinoma Classification

In 2011, a new IASLC/ATS/ERS classification of lung adenocarcinoma proposed significant changes to the 2004 WHO classification for resected tumors including (1) discontinuing the terms bronchioloalveolar carcinoma (BAC) and mixed subtype adenocarcinoma; (2) the addition of AIS as a preinvasive lesion to join atypical adenomatous hyperplasia; (3) addition of MIA; (4) classification of invasive adenocarcinomas according to the predominant subtype after comprehensive histologic subtyping by semiquantitatively estimating the percentage of the various subtypes present in 5% increments; (5) use of the term “lepidic” for a noninvasive component (previously classified as BAC) present as part of an invasive adenocarcinoma; (6) introducing the term “invasive mucinous adenocarcinoma” for adenocarcinomas formerly classified as mucinous BAC, excluding tumors that meet criteria for AIS or MIA; (7) discontinuing the subtypes of clear cell and signet ring adenocarcinoma and recognizing these as a feature when any amount is present, however small; (8) discontinuing the term mucinous cystadenocarcinoma and including these under the category of colloid adenocarcinoma.<sup>3,7,11,40</sup>

Subsequent to the 2011 IASLC/ATS/ERS lung adenocarcinoma classification and with the development of the 2015 WHO classification, it was decided to classify tumors formerly called large cell carcinomas that have pneumocyte marker expression (i.e., TTF-1 and/or Napsin A), as solid adenocarcinoma even if mucin is absent.<sup>1</sup> Solid adenocarcinoma must be distinguished from squamous cell carcinomas and large cell carcinomas, both of which may show rare cells with intracellular mucin. Solid adenocarcinoma should show at least two high-power fields with five or more cells showing intracytoplasmic mucin. The expression of TTF-1 and/or Napsin-A is sufficient not only for diagnosing solid adenocarcinoma, but for separating it from squamous cell carcinoma.<sup>41,42</sup>

Criteria for diagnosis of AIS and MIA are summarized in Tables 4 and 5. With regard to the term lepidic, resected

**TABLE 4. Adenocarcinoma In Situ<sup>a</sup>**

| Diagnostic criteria                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • A small tumor ≤3 cm <sup>3</sup>                                                                                                                                                                     |
| • A solitary adenocarcinoma                                                                                                                                                                            |
| • Pure lepidic growth                                                                                                                                                                                  |
| • No stromal, vascular or pleural invasion                                                                                                                                                             |
| • No pattern of invasive adenocarcinoma (such as acinar, papillary, micropapillary, solid, colloid, enteric, fetal or invasive mucinous adenocarcinoma).                                               |
| • No spread through air spaces                                                                                                                                                                         |
| • Cell type mostly nonmucinous (type II pneumocytes or Clara cells), rarely may be mucinous (tall columnar cells with basal nuclei and abundant cytoplasmic mucin, sometimes resembling goblet cells). |
| • Nuclear atypia is absent or inconspicuous                                                                                                                                                            |
| • Septal widening with sclerosis/elastosis is common, particularly in nonmucinous adenocarcinoma in situ                                                                                               |

<sup>a</sup>Modified from the articles by Travis et al.<sup>1,7,11</sup>

**TABLE 5.** Minimally Invasive Adenocarcinoma<sup>a</sup>

## Diagnostic criteria

- A small tumor  $\leq 3$  cm
- A solitary adenocarcinoma
- Predominantly lepidic growth
- $\leq 0.5$  cm invasive component in greatest dimension in any one focus
- Invasive component to be measured includes
  - Any histologic subtype other than a lepidic pattern (such as acinar, papillary, micropapillary, solid, colloid, fetal or invasive mucinous adenocarcinoma)
  - Tumor cells infiltrating myofibroblastic stroma
- Minimally invasive adenocarcinoma diagnosis is excluded if the tumor
  - Invades lymphatics, blood vessels, air spaces or pleura,
  - Contains tumor necrosis,
  - Spreads through air spaces
- The cell type mostly nonmucinous (type II pneumocytes or Clara cells), but rarely may be mucinous (tall columnar cells with basal nuclei and abundant cytoplasmic mucin, sometimes resembling goblet cells).


<sup>a</sup>Modified from the articles by Travis et al.<sup>1,2,11</sup>

primary lung adenocarcinomas that are lepidic predominant invasive adenocarcinoma should be called “adenocarcinoma, lepidic subtype” or “lepidic adenocarcinoma” with mention of the percentage of the lepidic component and listing of each of the other patterns present with their estimated percentage. Measurement of invasive size can be challenging in tumors with a lepidic component. If there is a single focus of invasion in a small tumor, it can be measured microscopically with a ruler on top of the slide on the microscope stage. If there are multiple foci of invasion or if the tumor does not fit onto a single slide, making ruler measurements difficult, recent data suggest that another way to estimate the invasive size is to sum the percentage of the invasive components and multiply this by the overall tumor diameter (i.e., a 2.0-cm total tumor size with 20% invasive components and 80% lepidic component would have an estimated invasive size of  $2.0 \times 0.2 = 0.4$  cm).<sup>43</sup> In the

differential with MIA, if the result is greater than 5 mm, a diagnosis of lepidic adenocarcinoma should be rendered. If there is doubt about tumor size after review of pathologic slides, correlation with a high-resolution computed tomography (CT) may be helpful to appreciate the amount of solid versus ground glass components in a lung nodule as these generally correspond to invasive versus lepidic components histologically.

The diagnosis of AIS or MIA can only be made in a resected tumor that has been submitted entirely for histologic evaluation, so complete histologic review can be performed to look for invasive foci. Therefore, when a small biopsy shows only a nonmucinous lepidic pattern, the diagnosis should be “adenocarcinoma with lepidic pattern” (Fig. 1A) adding a comment that this could be from a lesion that represents AIS, MIA, or invasive adenocarcinoma with a lepidic component (i.e., adenocarcinoma, lepidic subtype, or an invasive adenocarcinoma with a non-predominant lepidic component). Rarely, metastatic tumors may show a lepidic pattern, but they do not typically express TTF-1 in addition to the morphology of type II pneumocytes and/or club (Clara) cells. Correlation with CT findings can be informative to the likely final diagnosis (Fig. 1B). For example, if a biopsy shows a lepidic pattern and the CT shows a pure ground glass nodule, this would favor AIS or possibly MIA and less likely lepidic predominant adenocarcinoma (Fig. 1B), whereas if a mostly ground glass nodule also had a solid component measuring over 5 mm in size were present, this would favor lepidic predominant adenocarcinoma (Fig. 1C).<sup>44–47</sup> However, the final diagnosis of AIS or MIA requires a resection specimen, and these cannot be diagnosed in small biopsy specimens. It is reasonable to sample possible AIS or MIA lesions to save frozen tissue for research, but correlation with the CT findings should be made to be sure there are no suspicious solid areas for invasion. If suspicious areas are seen on CT and they are not represented in the histologic slides, the frozen sample may need to be processed for histologic examination to allow for a definitive diagnosis.


As most of the literature on MIA and AIS deals with tumors less than or equal to 2 to 3 cm, there is insufficient evidence that 100% disease-free survival can occur with such



**FIGURE 1.** A, Core biopsy shows an “adenocarcinoma with a lepidic pattern.” B, Correlation with the computed tomography (CT) scan shows a 2.5-cm pure ground glass nodule with no solid component, favoring a diagnosis of adenocarcinoma in situ (AIS), although a small invasive component or minimally invasive adenocarcinoma (MIA) cannot be excluded. C, This part solid nodule is from a resected lepidic predominant adenocarcinoma. If a core biopsy came from the ground glass area highlighted by the arrow, it could show the same pathologic findings as in A. It would be misleading to make a pathologic diagnosis of AIS in such a case as the entire lesion has not been sampled and the invasive component is not represented in the biopsy specimen.

tumors greater than 3 cm.<sup>7,40</sup> Therefore, if a tumor larger than 3 cm has been completely sampled histologically and shows either no invasion or less than or equal to 0.5 cm of invasion, the tumor should be classified as “lepidic adenocarcinoma, suspect AIS or MIA,” respectively.

In the 2015 WHO classification, the term “predominant” is not listed in the name for the major adenocarcinoma subtypes as it was in the 2011 IASLC/ATS/ERS lung adenocarcinoma classification. However, these tumors still should be classified according to the predominant subtype after evaluation of the tumor using comprehensive histologic subtyping to make a semiquantitative estimate of all of the different histologic patterns present in 5% increments. Classification of tumors according to the predominant subtype should not be interpreted to imply these are specific entities. Because lung adenocarcinomas frequently are composed of complex heterogeneous mixtures of patterns with a continuum from one pattern to the next (i.e., lepidic to papillary or acinar), comprehensive histologic typing provides a useful tool to estimate not only the predominant pattern but also minor components. It is very useful to document these percentages in pathology reports as it helps to document cases where there are small amounts of the micropapillary pattern, which have been shown to be associated with poor prognosis even in small amounts as it helps to compare multiple adenocarcinomas to document whether the percentages of patterns is similar or different.<sup>48</sup> Even though it is theoretically possible to have equal percentages of two prominent components, in practice, a single predominant component should be chosen. Recording of these percentages in a pathologic diagnosis in such a case makes it clear to the reader of a report when a tumor has relatively even mixtures of several patterns versus a clear single predominant pattern. One point of frequent questioning is when an area of adenocarcinoma shows an acinar or lepidic pattern, and there are tumor cells within air spaces in a micropapillary pattern; this should be classified as micropapillary and not acinar or lepidic (Fig. 2). Several studies have shown that the cribriform



**FIGURE 2.** Adenocarcinoma with micropapillary pattern. When an airspace contains a micropapillary pattern (arrowheads), even if it is surrounded by lepidic or acinar structures, it should be classified as a micropapillary pattern.

pattern is associated with worse prognosis.<sup>49–51</sup> Recognition of this pattern may be a way to recognize a higher grade of tumors with acinar growth.


A reproducibility study of classical and difficult selected images of the major lung adenocarcinoma subtypes circulated among a panel of 26 expert lung cancer pathologists documented  $\kappa$ -values of  $0.77 \pm 0.07$  and  $0.38 \pm 0.14$ , respectively.<sup>52</sup> A study of reproducibility for predominant pattern showed moderate to good  $\kappa$ -values of 0.44 to 0.72 for pulmonary pathologists. For untrained pathologists,  $\kappa$ -values were expectedly lower ranging from 0.38 to 0.47, but these improved after a training session to 0.51 to 0.66 and reevaluation by the same reviewers led to very high  $\kappa$ -values between 0.79 and 0.87.<sup>53</sup>

### Spread Through Air Spaces

Since the 2011 IASLC/ATS/ERS lung adenocarcinoma classification was published, an additional pattern of invasion is now more clearly recognized consisting of spread through air spaces (STAS). STAS consists of micropapillary clusters, solid nests, or single cells beyond the edge of the tumor into air spaces in the surrounding lung parenchyma (Fig. 3). It probably contributes to the significantly increased recurrence rate for patients with small stage I adenocarcinomas who undergo limited resections<sup>54</sup> and the worse prognosis observed by others.<sup>55–57</sup> As this represents a manifestation of tumor spread, this is not included in the percentage measurement of subtype patterns in comprehensive histologic typing or in measurement of invasive size. STAS is now incorporated into the definition of invasion that is used to separate lepidic adenocarcinomas from MIA and AIS. STAS is a pattern of invasion to be reported similar to visceral pleural and vascular invasion.

### Comparing Multiple Lung Adenocarcinomas

Comprehensive histologic subtyping can be useful in comparing multiple lung adenocarcinomas in a single patient to distinguish multiple primary tumors from intrapulmonary metastases. This has a great impact on staging for patients with multiple lung adenocarcinomas. Recording the percentages of the various histologic subtypes in 5% increments, not just the most predominant type, allows these data to be used to compare multiple adenocarcinomas, particularly if the slides of a previous tumor are not available at the time of review of the additional lung tumors. In addition to comprehensive histologic subtyping, other histologic features of the tumors such as cytologic (clear cell or signet ring features) or stromal (desmoplasia or inflammation) characteristics may be helpful to compare multiple tumors.<sup>48</sup> It is likely that poorly differentiated components such as solid and micropapillary may be enriched in some metastatic foci, so one does not necessarily expect an identical percentage distribution of patterns in intrapulmonary metastases, and in such cases, other stromal or cytologic characteristics may play a more important role. Nevertheless this is a powerful tool for morphologic comparison of multiple tumors. Several genetic studies have addressed this problem,<sup>48,58–63</sup> but the role of molecular studies including what platform to utilize and how to interpret the results remains to be established. Ultimately, a multidisciplinary



**FIGURE 3.** Invasion of adenocarcinoma in the pattern of spread through air spaces (STAS). *A*, Tumor cells are present within airspaces in the lung parenchyma beyond the edge of the tumor (arrows). *B*, These consists of micropapillary clusters and single cells (arrows).

approach is needed to address this problem incorporating clinical, radiologic, molecular, and pathologic information.

### Prognostic and Predictive Implications of Adenocarcinoma Comprehensive Subtyping

Despite the challenges in distinguishing some patterns from each other, since the principle of comprehensive histologic subtyping was introduced in the 2011 IASLC/ATS/ERS classification, there are a growing number of studies of resected lung adenocarcinomas that have demonstrated its utility in identifying significant prognostic subsets and molecular correlations according to the predominant patterns.<sup>31,32,43,64–69</sup> The prognosis for lepidic predominant adenocarcinoma in stage I patients is excellent<sup>31,32,43,69,70</sup>; most of those tumors that recur have some high risk factor such as a close margin in limited resection and presence of a micropapillary component or invasion of blood vessels and/or pleura.<sup>43</sup> The solid and micropapillary subtypes are associated with poor prognosis.<sup>64,66–68,70,71</sup> The presence of the micropapillary subtype is a poor prognostic

factor for overall survival<sup>72</sup> and for recurrence in patients with limited resections.<sup>73</sup> Solid predominant subtype has also been shown to be an independent predictor of early, extrathoracic, multisite recurrence, and poor postrecurrence survival.<sup>74</sup>

New data suggest that micropapillary or solid predominant subtyping predicts improved responsiveness to adjuvant chemotherapy compared with acinar or papillary predominant tumors in surgically resected lung adenocarcinoma patients when analyzed by disease-free survival and specific disease-free survival.<sup>75</sup>

### SQUAMOUS CELL CARCINOMA

The terminology and criteria for squamous cell carcinoma diagnosis in small biopsies are discussed above, and the comments below refer to these issues in resection specimens. In the 2004 WHO classification, the major subtypes included papillary, clear cell, small cell, and basaloid carcinoma. However, this was not very meaningful as the papillary, clear cell, and small cell subtypes are very uncommon.<sup>35</sup> In retrospect, the term small cell variant of squamous cell carcinoma was probably not a good choice because if it were used in clinical practice, it could be confused with small cell carcinoma, so this term is now discontinued. As with lung adenocarcinoma, clear cell change is now regarded as a cytologic feature that can occur in keratinizing or nonkeratinizing squamous cell carcinoma, so this is no longer recognized as a formal subtype, although it can be referred to in a diagnosis as “with clear cell features” with the amount mentioned even if in a small percentage. In addition, with the new importance of separating adenocarcinoma and squamous cell carcinoma, it was learned through molecular and immunohistochemical studies that some adenocarcinomas have a very squamous-like morphology.<sup>41,42</sup> So in the absence of unequivocal keratinization, immunohistochemistry with positive squamous markers such as p40 or p63 is required to diagnose surgically resected nonkeratinizing squamous cell carcinoma. Furthermore, with the recognition that the former basaloid carcinomas actually express squamous markers, these tumors were moved from the category of large cell carcinoma to become a subtype of squamous cell carcinoma. Genetic data also support that basaloid squamous cell carcinomas show a specific mRNA expression profile, factors controlling cell cycle, transcription, chromatin, and splicing with prevalent expression in germ line and stem cells and underexpress typical genes seen in other squamous cell carcinomas.<sup>76</sup> For these reasons, the subtyping of squamous cell carcinoma was modified to consist of keratinizing, nonkeratinizing, and basaloid subtypes, similar to the Head and Neck WHO Classification of nasopharyngeal carcinomas (Table 1).<sup>77</sup> Tumors are classified as keratinizing subtype if any amount of keratinization is present and basaloid squamous cell carcinoma if this component is greater than 50% of the tumor, regardless of the presence of any keratinization. In tumors with 50% or less of a basaloid component, this can be acknowledged in the diagnosis “with basaloid features.”<sup>71</sup> There does not seem to be prognostic significance to keratinizing versus nonkeratinizing squamous carcinomas.<sup>35</sup> Some studies suggest a poorer prognosis for basaloid squamous cell carcinomas,<sup>76,78,79</sup> but other data do not support this.<sup>35,80,81</sup>

There is currently no clear clinical implication to the subtyping of squamous cell lung cancer. However, there is an increasing amount of clinical data on new therapies for this tumor (e.g., immunotherapy and new targeted therapies).<sup>82</sup>

### LARGE CELL CARCINOMA

The entity large cell carcinoma can only be diagnosed in a surgical resected tumor, so this term should not be applied to small biopsies or cytology (see above). In the 2004 WHO classification, large cell carcinoma included several variants such as LCNEC, basaloid carcinoma, lymphoepithelioma-like carcinoma, clear cell carcinoma, and large cell carcinoma with rhabdoid phenotype.<sup>3</sup> In addition, in the 2004 WHO Classification, there was no role for immunohistochemistry using adenocarcinoma or squamous markers in assessing these tumors. However, in the 2015 WHO Classification, carcinomas showing a solid pattern are now reclassified as solid adenocarcinoma or non-keratinizing squamous cell carcinoma, if they show positive staining for markers such as TTF-1 or p40, respectively.<sup>1</sup> This decision was based on genetic and immunohistochemical studies indicating that tumors previously classified as large cell carcinomas were a heterogeneous group of tumors with adenocarcinoma, squamous cell differentiation, or a null immunophenotype and genotype.<sup>21,83,84</sup> Poorly differentiated carcinomas are regarded to have a null immunophenotype if they lack clear pneumocyte (i.e., TTF-1), squamous (p40), or neuroendocrine (chromogranin, synaptophysin, CD56) marker staining patterns. Tumors with adenocarcinoma or null immunophenotype typically showed an adenocarcinoma genetic profile, and those with a squamous immunophenotype showed a squamous genetic profile.<sup>21,83–85</sup> Furthermore, epidemiologic evidence from the National Cancer Institute (NCI) Surveillance Epidemiology and End Results registry indicated that the diagnosis of large cell carcinoma started to decline about the time that TTF-1 was introduced into clinical diagnosis, so this probably reflects that practicing pathologists started to reclassify large cell carcinomas.<sup>86</sup>

The other large cell carcinoma subtypes from the 2004 WHO classification are reclassified as follows. LCNEC is now grouped with the other neuroendocrine tumors. Basaloid carcinoma is moved to a subtype of squamous cell carcinoma. Lymphoepithelioma-like carcinoma is moved to a group of “other and unclassified carcinomas.” Clear cell carcinoma and rhabdoid phenotype are now regarded as a cytologic features rather than a specific histologic subtype, as these can occur in a variety of histologic types including adenocarcinoma or squamous cell carcinoma (Table 1).

### NEUROENDOCRINE TUMORS

In the 1981, prior WHO classifications the carcinoid tumors, small cell lung carcinoma (SCLC) and LCNEC were grouped separately. However, in the current classification they are grouped together.<sup>1</sup> The tumors are listed in the order of their frequency with SCLC first as it is the most common. Although some have suggested there should be a uniform neuroendocrine tumor classification system throughout the body including the lung, similar to the one used in the gastrointestinal tract and pancreas, a leading organization, the European

Neuroendocrine Tumor Society, has endorsed the WHO classification for pulmonary neuroendocrine tumors.<sup>87</sup>

Despite the grouping of these tumors together, it is clear that the carcinoids have major clinical, epidemiologic, histologic, and genetic differences compared with the high-grade SCLC and LCNEC. Carcinoid patients are significantly younger, have a better prognosis, and lack the strong association with smoking that applies for SCLC and LCNEC. Also compared with carcinoid tumors, SCLC and LCNEC have much higher mitotic rates, more necrosis and can show combinations with other lung cancer types including adenocarcinoma or squamous cell carcinoma.<sup>87</sup> Carcinoid tumors also have very few genetic abnormalities compared with SCLC and LCNEC.<sup>85,88</sup>

Although, in many cases, SCLC and carcinoid tumors can be diagnosed on good quality tumor material with a high-quality hematoxylin and eosin-stained section and in well preserved cytologic samples, immunohistochemistry can be very helpful in diagnosing pulmonary neuroendocrine tumors. The role of Ki-67 is mainly to separate the high-grade SCLC and LCNEC from the carcinoid tumors, especially in small biopsies with crushed and/or necrotic tumor cells.<sup>89,90</sup> Data are conflicting regarding its use in separating typical from atypical carcinoid tumors, so it is not recommended in this setting.<sup>87,89,91</sup>

Mitosis counting methods were not specified in the 2004 WHO Classification, but more detail is provided in the 2015 book. Careful counting of mitoses is essential as it is the most important histologic criteria for separating typical from atypical carcinoid and the carcinoids from the high-grade SCLC and LCNEC. Mitoses should be counted in the areas of highest activity and per 2 mm<sup>2</sup> rather than 10 high-power fields. Because of the differences in microscope models, adjustments need to be made in the number of high-power fields reviewed to assess a 2 mm<sup>2</sup> area of tumor.<sup>92</sup> In tumors that are near the cutoffs of 2 or 20 mitoses per 2 mm<sup>2</sup>, at least three sets of 2 mm<sup>2</sup> should be counted and the mean used for determining the mitotic rate, rather than the single highest rate. For typical and atypical carcinoid tumors, mitotic rate and necrosis status should be included in pathology reports.

Because of recognition of the potential overlap in the morphology of LCNEC and basaloid squamous cell carcinoma, it can be helpful to confirm negative squamous markers (i.e., p40) in TTF-1-negative tumors that otherwise meet criteria for LCNEC. In 10–20% of NSCC, neuroendocrine differentiation can be demonstrated. This is not formally recognized as class of tumors in the 2015 WHO Classification, as there is no proven clinical significance to this finding.<sup>1,3,7</sup>

### SARCOMATOID CARCINOMA

Sarcomatoid carcinoma is a general term that includes pleomorphic carcinoma, carcinosarcoma, and pulmonary blastoma. For this reason, it is best to use the specific term for these entities whenever possible rather than the general term. This also may avoid any confusion with a true sarcoma. These tumors are rare accounting for less than 1% of all lung cancers.<sup>93</sup> There are no major changes in the terminology or diagnostic criteria for these tumors since the 2004 Classification. One new aspect is the recommendation for molecular testing according to known genetic abnormalities associated with histologic components (i.e., tumors with an adenocarcinoma component should be

tested for *EGFR* mutation and *ALK* rearrangement). The diagnoses of pleomorphic, spindle cell, or giant cell carcinoma cannot be made on small biopsies or cytology, and recommendations for diagnostic terminology in these types of specimens are discussed above. It is very difficult to diagnose carcinosarcoma or pulmonary blastoma in small biopsies and cytology, but if material is obtained that fulfills diagnostic criteria, it is possible. Prognosis for all these tumors is poor.

Pleomorphic carcinoma is a poorly differentiated NSCC namely a squamous cell carcinoma, adenocarcinoma, or undifferentiated NSCC that contains at least 10% spindle and/or giant cells or a carcinoma consisting only of spindle and giant cells. The prevalence of *KRAS* (in up to 38% of cases)<sup>94,95</sup> and *EGFR* mutations (in up to 25% of cases)<sup>96–98</sup> partially reflects the tumor components (i.e., adenocarcinoma), patient ethnicity, and smoking habits.<sup>99</sup>

Spindle cell carcinoma consists of an almost pure population of epithelial spindle cells, with no differentiated carcinomatous elements.

Giant cell carcinoma consists almost entirely of tumor giant cells (including multinucleated cells), with no differentiated carcinomatous elements. Definite diagnosis may only be made on a resected tumor. The specific histological components should be mentioned in the diagnosis.

Carcinosarcoma is a malignant tumor that consists of a mixture of NSCLC (typically squamous cell carcinoma or adenocarcinoma) and sarcoma-containing heterologous elements, such as rhabdomyosarcoma, chondrosarcoma, and osteosarcoma. Carcinosarcomas are clonal tumors<sup>100–102</sup> developing through sarcomatoid change in a carcinoma.<sup>100,102</sup> *TP53* mutations are often present in carcinosarcoma,<sup>101,103</sup> whereas *KRAS* mutations occur less frequently,<sup>101,103</sup> and *EGFR* mutations are very uncommon.<sup>103,104</sup>

Pulmonary blastoma is a biphasic tumor that consists of fetal adenocarcinoma (typically low grade) and primitive mesenchymal stroma. Foci of specific mesenchymal differentiation (osteosarcoma, chondrosarcoma, or rhabdomyosarcoma) may also be present but are not required for the diagnosis. Pulmonary blastoma and well-differentiated fetal adenocarcinoma (a putative precursor lesion) are frequently associated with missense mutations in exon 3 of *CTNNB1*, responsible for activation of the Wnt pathway through aberrant nuclear/cytoplasmic localization of  $\beta$ -catenin protein.<sup>103,105–107</sup> *TP53* mutation and both p53 and MDM2 protein accumulation are occasionally detected in pulmonary blastoma.<sup>101,103,108</sup>

### NUT CARCINOMA


Carcinomas associated with chromosomal rearrangement in the *NUT* gene are called NUT carcinomas. These are poorly differentiated carcinomas genetically defined by the presence of *NUT* gene rearrangement.<sup>109,110</sup> This consists of a chromosomal translocation between the *NUT* gene (*NUTM1*) on chromosome 15q14 and other genes: *BRD4* on chromosome 19p13.1 (70%), *BRD3* on chromosome 9q34.2 (6%), or an unknown partner gene (24%).<sup>111</sup> Fewer than 100 cases of NUT carcinoma have been reported. Although it was originally thought to be a disease of children and younger adults, NUT carcinoma can affect people of any age, affecting males and females equally.<sup>109,110</sup>

This tumor was recognized in the thymus in the 2004 WHO classification as a carcinoma with t(15;19) translocation, and it is also referred to as NUT midline carcinoma. Pathologically, it consists of sheets and nests of small-sized to intermediate-sized undifferentiated cells with a monomorphic appearance (Fig. 4A).<sup>110</sup> Nuclei have irregular contours and granular to coarse chromatin. Foci of abrupt keratinization are often present. Immunohistochemistry is positive in more than 50% of tumor cells with a speckled nuclear positivity (Fig. 4B).<sup>112</sup> NUT carcinoma is a very aggressive tumor with a median survival of 7 months.<sup>113</sup>

### TUMORS OTHER THAN LUNG CANCER WITH SIGNIFICANT CHANGES FROM THE 2004 WHO CLASSIFICATION

#### Sclerosing Pneumocytoma

In this classification, sclerosing hemangioma is moved from a group of "Miscellaneous tumors" where it was



**FIGURE 4.** Nuclear protein in testis (NUT) carcinoma. A, This poorly differentiated carcinoma consists of large cells with moderate eosinophilic cytoplasm and prominent nucleoli. No clear glandular or squamous differentiation is seen. B, Immunohistochemistry with NUT antibody shows diffuse strong staining with a granular nuclear pattern.

classified in both the 1999 and 2004 WHO Classifications<sup>3,6</sup> to the group of "Adenomas" in the current classification. It has been recognized for many years that sclerosing hemangioma is not a vascular tumor. Multiple papers have documented that this tumor is actually derived from primitive respiratory epithelial cells that express TTF-1 in the solid as well as surface tumor cells.<sup>114,115</sup> This tumor characteristic has become widely recognized and accepted making it an appropriate time to reclassify this tumor as an adenoma. Sclerosing pneumocytoma is a tumor of pneumocytic origin with a dual population of surface cells resembling type II pneumocytes and round cells, with slightly different histogenetic profiles. Most tumors have at least three of four primary growth patterns: solid, papillary, sclerosing, and hemorrhagic. The key feature of sclerosing pneumocytoma is the presence of two cell types: cuboidal surface cells and stromal round cells, both of which are considered to be neoplastic.<sup>116</sup> The surface cells are cuboidal and morphologically similar to type II pneumocytes. These tumors can be very challenging to diagnose in frozen section, small biopsies, and cytology where they can easily be mistaken for adenocarcinoma or carcinoid tumors. Despite the very rare frequency of metastases, these tumors typically have a benign clinical course.<sup>114</sup>

### Pulmonary Hamartoma

Pulmonary hamartomas are neoplasms composed of varying amounts of at least two mesenchymal elements (such as cartilage, fat, connective tissue, and smooth muscle), combined with entrapped respiratory epithelium. Because hamartomas in other parts of the body are generally not regarded to be neoplasms, there was a debate if hamartomas in the lung should have an International Classification of Diseases for Oncology code in this classification. However, because multiple genetic studies have established that these are true neoplasms, they have been assigned a new International Classification of Diseases for Oncology code and the diagnostic term is "pulmonary hamartoma," rather than just hamartoma. Pulmonary hamartomas have a high frequency of the translocation t(3;12)(q27-28;q14-15), resulting in gene fusion of the high mobility group protein gene *HMGA2* and the *LPP* gene. The *HMGA2-LPP* fusion gene usually consists of exons 1-3 of *HMGA2* and exons 9-11 of *LPP* and seems to be expressed in all tumors with this translocation.<sup>117-119</sup>

Pulmonary hamartomas are composed predominantly of chondroid or chondromyxoid tissue intermixed with variable proportions of other mesenchymal components, including fat, myxoid fibrous connective tissue, smooth muscle, and bone. Clefts of normal respiratory epithelial cells represent entrapment by the expanding mesenchymal growth. Endobronchial pulmonary hamartomas may have a prominent adipose tissue component. Immunohistochemical stains show reactivity for mesenchymal markers and sex steroid receptors, but immunohistochemistry is not usually necessary for diagnosis.<sup>120</sup>

### PEComatous Tumors

PEComatous tumors are thought to arise from perivascular epithelioid cells. In the lung, they can take several

forms: (1) a diffuse multicystic proliferation termed LAM; (2) more rarely, a benign localized mass termed a clear cell tumor or PEComa; and (3) exceptionally, a diffuse proliferation with overlapping features between LAM and clear cell tumor. These lesions are part of the spectrum of PEComatous tumors that arise at several sites throughout the body, originating from the perivascular epithelioid cells, although no counterpart in normal tissue has yet been identified. In the 1999 WHO<sup>6</sup> Classification, LAM was classified under tumor-like lesions, and in 2004,<sup>3</sup> it was moved to mesenchymal tumors. In both 1999 and 2004 WHO Classifications, clear cell tumors were grouped under "Miscellaneous tumors." However, in the 2015 WHO Classification, these lesions are grouped together under the title "PEComatous tumors" with three groups of tumors: (1) LAM, (2) PEComa, benign including clear cell tumor, and (3) PEComa, malignant.<sup>1</sup> Historically LAM was considered an interstitial lung disease but it is now considered to be a low-grade destructive metastasizing neoplasm, as the lesional cells usually have growth-promoting biallelic mutations in the tuberous sclerosis gene *TSC2*. Lymphangioleiomyomatosis cells also show evidence of clonal origin, as well as invasive and metastatic potential further supporting the theory of a neoplastic underpinning.<sup>121-124</sup> There is a very rare association between clear cell tumors and tuberous sclerosis.<sup>125</sup> Isolated cases with more diffuse features that overlap with LAM have also been described,<sup>126</sup> called diffuse PEComatosis.<sup>127</sup>


Lymphangioleiomyomatosis consists of a proliferation of plump spindle-shaped myoid cells with typically pale eosinophilic cytoplasm. These are usually found in the walls of the cystic air spaces, where their growth may be overt and nodular, although some cases may be very subtly infiltrative, to the extent that multiple levels are required to identify the lesional cells. Lesional cells may infiltrate blood vessels and lymphatics, causing secondary pulmonary hemorrhage. Lymphangioleiomyomatosis can be associated with micronodular type II pneumocyte hyperplasia, particularly in individuals with tuberous sclerosis.<sup>128</sup> Clear cell tumors consist of rounded or oval cells with distinct cell borders and abundant clear or eosinophilic cytoplasm. There is mild variation in nuclear size, and nucleoli may be prominent, but mitoses are usually absent.<sup>129,130</sup> The presence of necrosis is extremely rare and should lead to consideration of malignancy,<sup>126,129,131</sup> as should significant mitotic activity and an infiltrative growth pattern. Thin-walled sinusoidal vessels are characteristic. Because of the glycogen-rich cytoplasm, there is usually strong periodic acid-Schiff positivity that is removed with diastase digestion.<sup>132</sup> Cases with diffuse PEComatosis show features overlapping between LAM and clear cell tumor.<sup>127</sup> Both LAM and clear cell tumor stain most consistently for HMB45, melan A, and microphthalmia transcription factor. Clear cell tumors may also stain for S100. Lymphangioleiomyomatosis stains for smooth muscle actin and is S100-negative; some cases also stain for the estrogen and progesterone receptors. The *TSC* mutations that occur in LAM result in abnormal signaling through the mammalian target of rapamycin (mTOR) pathway.<sup>133</sup>

### Epithelioid Hemangioendothelioma

Epithelioid hemangioendothelioma is a low-grade to intermediate-grade malignant vascular tumor composed of solid nests and short cords of epithelioid endothelial cells in a myxohyaline stroma.<sup>134,135</sup> The new information regarding this tumor is recognition of a translocation involving the *WWTR1* and *CAMTA1* genes and prognostic factors. The details of the histologic features are described previously.<sup>3,134,135</sup> They may be low or intermediate grade with the latter distinguished by the presence of necrosis, increased mitotic activity (mean 2/2 mm<sup>2</sup>), and greater nuclear atypia.<sup>134</sup> The vascular markers CD31, CD34, and FLI1 are more sensitive than factor VIII, and most epithelioid hemangioendothelioma expresses these markers. Focal cytokeratin expression is present in 25% to 30% of cases.<sup>134</sup> A recurrent t(1;3)(p36.3;q25) chromosomal translocation is characteristic of epithelioid hemangioendothelioma.<sup>134,136</sup> The translocation involves two genes, *WWTR1* (3q25), which encodes a transcriptional coactivator that is highly expressed in endothelial cells, and *CAMTA1* (1p36), a DNA-binding transcriptional regulatory protein that is normally expressed during brain development.<sup>137–139</sup> A subset of epithelioid hemangioendothelioma occurring in young adults shows recently described *YAP1-TFE3* fusions.<sup>140</sup> Epithelioid hemangioendothelioma is a low-grade to intermediate-grade malignant tumor with metastatic potential and a 5-year survival rate of 60%. Prognosis is worse for intermediate grade compared with low-grade tumors and can be as low as 20%.<sup>134</sup> Negative prognostic indicators include extensive intrapulmonary and pleural spread, weight loss, anemia, and hemorrhagic pleural effusions.<sup>141</sup>

### Pulmonary Myxoid Sarcoma with an *EWSR1-CREB1* Translocation

Primary pulmonary myxoid sarcoma is a malignant tumor that typically arises in the airways. It predominantly consists of lobules of delicate, lacelike strands, and cords of mildly atypical round and spindle cells within a prominent myxoid stroma. Primary pulmonary myxoid sarcoma was first described in 1999.<sup>142</sup> It is seen most often in young adult females, but fewer than 15 cases have been published.<sup>143,144</sup> The tumor is characterized by distinct histological features and an *EWSR1-CREB1* fusion (Fig. 5). Although *EWSR1-CREB1* is also found in other tumors (such as angiomatoid fibrous histiocytoma<sup>144</sup> and clear cell sarcomas),<sup>145</sup> primary pulmonary myxoid sarcomas are morphologically different from these entities. At low power, pulmonary myxoid sarcomas have a lobulated architecture, with an endobronchial location. A fibrous pseudocapsule may be present. Tumors are typically composed of spindle, stellate, and polygonal cells, with a predominant reticular network of delicate lacelike strands and cords within a prominent myxoid stroma that may be lightly basophilic, although more solid areas may be found. A minority have a predominantly solid architecture with a more patternless distribution of cells within the myxoid stroma, which may be focally fibrous (Fig. 5A). In one case, cells showed focal multinucleation. Cellular atypia is generally mild to moderate in extent, although rare cases have shown focal marked atypia and multinucleation. Mitotic rates of up to 32



**FIGURE 5.** Primary pulmonary myxoid sarcoma. A, Spindle and rounded cells with typically bland nuclei show a lace-like or reticular architecture within sparsely cellular myxoid stroma, with a mixed chronic inflammatory infiltrate. B, Fluorescent in situ hybridization shows split red and green signals (thin arrows) with *EWSR1* break-apart probes in tumor nuclei, consistent with the presence of rearrangements of this gene, contrasting with the fusion signal in a non-rearranged gene (thick arrow). C, Direct sequencing confirms the presence of *EWSR1-CREB1* fusions, which predominantly involve exon 7 of each gene (lower diagram), or more rarely occur between exon 7 of *EWSR1* and exon 8 of *CREB1* (upper diagram). B and C, Reprinted from Thway et al.<sup>143</sup>

mitoses per 2 mm<sup>2</sup> with atypical forms are described, although the majority shows less than 5 mitoses per 2 mm<sup>2</sup>. Necrosis is seen in about 50% of tumors and tends to be focal. Most cases

have a patchy background chronic inflammatory cell infiltrate of mainly lymphocytes and plasma cells. Vascular invasion is rare.<sup>143</sup> All tumors express vimentin, and 60% show weak and focal staining for epithelial membrane antigen. Other common markers are negative, in particular cytokeratins, S100, smooth muscle actin, desmin, CD34, and neuroendocrine markers. The myxoid stroma is positive for Alcian blue, with staining sensitive to treatment with hyaluronidase.<sup>142</sup>

*EWSR1* rearrangements are detectable by fluorescent in situ hybridization, with real-time reverse transcriptase polymerase chain reaction analysis showing *EWSR1-CREB1* fusion transcripts that have been confirmed with direct sequencing (Fig. 5, B and C). In assessable cases, the break point in *EWSR1* involved exon 7, whereas for the *CREB1* gene, exon 7 was involved in six cases and exon 8 in one. Cases have been assessed for fusion transcripts of *NR4A3EWSR1* and *NR4A3TAF15*, but neither were detected.<sup>143</sup>

### Myoepithelial Tumors

Myoepithelial tumors of the lung are rare, but they are gaining increasing recognition with the discovery of *EWSR1* gene rearrangements as a marker. These tumors show predominant or exclusive myoepithelial differentiation, and malignant myoepithelial tumors are classified as myoepithelial carcinomas. Myoepithelial tumors differ from mixed tumors, in that mixed tumors also show ductal differentiation. Histologically, the tumors show a spectrum of trabecular or reticular patterns, with abundant myxoid stroma (Fig. 6).<sup>146-151</sup> The tumor cells are epithelioid or spindled, and the nuclei are uniform, with eosinophilic or clear cell cytoplasm (Fig. 6). Cells with a plasmacytoid appearance and cytoplasmic hyaline inclusions can be present.<sup>146,147</sup> Myoepithelial carcinomas also show malignant features, such as a high mitotic rate, necrosis, or nuclear atypia.<sup>148,151</sup> Immunohistochemistry shows that most tumors stain positively for keratin, S100, calponin, and glial fibrillary acidic protein. Smooth muscle actin and p63 (or p40) may also be positive. Staining for desmin and CD34 is negative.<sup>134,146,147</sup> *EWSR1* gene rearrangement can be found in pulmonary myoepithelial tumors




FIGURE 6. Myoepithelioma. The tumor shows clusters of small round cells with focal hyaline stroma.

*EWSR1-ZNF444*, and *FUS* gene rearrangements were found in two malignant tumors that showed clear cell and spindle cell morphology.<sup>152</sup>

### Erdheim-Chester disease

Erdheim-Chester disease is newly added to the classification of lymphoproliferative disorders as it has become better characterized clinically, pathologically, and genetically. It is a rare xanthogranulomatous histiocytosis characterized by infiltration of the skeleton and viscera by lipid-laden histiocytes. In the lung, this leads to interstitial fibrosis with a perilymphatic distribution. Erdheim-Chester disease involves the lungs in 20% to 30% of patients,<sup>153,154</sup> and there is a slight male predominance. Peak incidence occurs within the fifth to seventh decade, with a range of 4 to 87 years and a mean age at diagnosis of 53 years.<sup>153-156</sup> Pulmonary symptoms are typically cough and dyspnea, although pulmonary involvement may also be asymptomatic.<sup>153</sup> Pleural effusions occur in about 20% of patients.<sup>155</sup> General symptoms consist of mild bone pain (occasionally




FIGURE 7. Erdheim-Chester disease. A, Low power shows diffuse interstitial infiltrates along lymphatic routes: the pleura (arrows) and bronchovascular bundles (arrowheads) mark a few of the many affected bronchovascular bundles. B, High power shows thickening of the interstitium by sheets of histiocytic cells (arrowheads) adjacent to areas of fibrosis.

associated with soft tissue swelling), fever, weight loss, and weakness. Other manifestations include exophthalmos, diabetes insipidus, kidney failure, and cardiac or neurological symptoms. The serum lipid profile is relatively normal. The lung is involved in more than half of all cases with thoracic involvement, with septal and subpleural thickening, poorly defined centrilobular nodular, and ground-glass opacities, and lung cysts being reported.<sup>155,157</sup> Mediastinal infiltration, pleural thickening, and effusions are also commonly seen.<sup>157</sup> Architecturally, histiocytic infiltration and fibrosis predominate along the distribution of the pulmonary lymphatics (visceral pleura, bronchovascular bundles, and interlobular septa; Fig. 7A). Histiocytes are typically foamy, with Touton giant cells often seen (Fig. 7B). This is associated with variably dense fibrosis, lymphocytes, plasma cells, and eosinophils. Immunohistochemistry confirms the monocyte/macrophage lineage of the lipid-laden foamy histiocytes and giant cells by their expression of Factor XIIIa, lysozyme, MAC387, CD68 (KP1), CD4, alpha-1 antichymotrypsin, alpha-1 antitrypsin, and S100 protein (variable).<sup>158</sup> They are negative for CD1a. B-rapidly accelerated fibrosarcoma (*BRAF*) V600E mutations have been detected in 54% of patients,<sup>159</sup> and the histiocytic proliferation has been shown to be clonal in some studies<sup>160,161</sup> but not in others.<sup>162</sup> Sustained responses to vemurafenib, a *BRAF* inhibitor, have been reported in patients with *BRAF* (V600E) mutated Erdheim-Chester disease.<sup>163,164</sup>

## REFERENCES

- Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer, 2015.
- Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization (WHO), 2000.
- Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC, 2004.
- World Health Organization. Histological typing of lung tumours. Geneva: World Health Organization, 1967.
- World Health Organization. Histological typing of lung tumors. Geneva: World Health Organization, 1981.
- Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, in collaboration with LHS, Countries pf. Histological typing of lung and pleural tumors. Berlin: Springer, 1999.
- Travis WD, Brambilla E, Noguchi M, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. *J Thorac Oncol* 2011;6:244–285.
- Nivolumab approved for lung cancer. *Cancer Discov* 2015;5:OF1.
- Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *J Thorac Oncol* 2013;8:823–859.
- Leigh NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. *J Clin Oncol* 2014;32:3673–3679.
- Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. *Arch Pathol Lab Med* 2013;137:668–684.
- Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. *J Thorac Oncol* 2009;4:1202–1211.
- Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. *J Thorac Oncol* 2010;5:442–447.
- Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. *J Thorac Oncol* 2010;5:436–441.
- Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. *J Clin Pathol* 2000;53:537–540.
- Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. *J Thorac Oncol* 2010;5:411–414.
- Turner BM, Cagle PT, Sainz IM, Fukuoaka J, Shen SS, Jagirdar J, Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. *Arch Pathol Lab Med* 2012;136:163–171.
- Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. *Mod Pathol* 2012;25:405–415.
- Pelosi G, Fabbri A, Bianchi F, et al. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. *J Thorac Oncol* 2012;7:281–290.
- Nonaka D. A study of ΔNp63 expression in lung non-small cell carcinomas. *Am J Surg Pathol* 2012;36:895–899.
- Rekhtman N, Tafe LJ, Chaff JE, et al. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. *Mod Pathol* 2013;26:511–522.
- Travis WD, Brambilla E, Rieley GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. *J Clin Oncol* 2013;31:992–1001.
- Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012;489:519–525.
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014;511:543–50.
- Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. *Sci Transl Med* 2013;5:209ra153.
- Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. *Cancer* 2010;116:659–669.
- Kadota K, Suzuki K, Kachala SS, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Mod Pathol* 2012;25:1117–1127.
- Nakazato Y, Maeshima AM, Ishikawa Y, et al. Interobserver agreement in the nuclear grading of primary pulmonary adenocarcinoma. *J Thorac Oncol* 2013;8:736–743.
- Nakazato Y, Minami Y, Kobayashi H, et al. Nuclear grading of primary pulmonary adenocarcinomas: correlation between nuclear size and prognosis. *Cancer* 2010;116:2011–2019.
- Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. *Am J Surg Pathol* 2010;34:1155–1162.
- Yoshizawa A, Motoi N, Rieley GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. *Mod Pathol* 2011;24:653–664.
- Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. *J Clin Oncol* 2012;30:1438–1446.
- Duhig EE, Detrick A, Godbolt DB, et al. Mitosis trumps T stage and proposed international association for the study of lung cancer/American thoracic society/European respiratory society classification for prognostic value in resected stage I lung adenocarcinoma. *J Thorac Oncol* 2015;10:673–681.
- von der Thüsen JH, Tham YS, Pattenden II, et al. Prognostic significance of predominant histologic pattern and nuclear grade in resected adenocarcinoma of the lung: potential parameters for a grading system. *J Thorac Oncol* 2013;8:37–44.

35. Kadota K, Nitadori J, Woo KM, et al. Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes. *J Thorac Oncol* 2014;9:1126–1139.
36. Sigel CS, Rudomin DE, Sima CS, et al. Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. *Cancer Cytopathol* 2012;120:35–43.
37. Kadota K, Yeh YC, Villena-Vargas J, et al. Tumor budding correlates with protumor immune microenvironment and is an independent prognostic factor for recurrence of stage I lung adenocarcinoma. *Chest* 2015 [Epub ahead of print].
38. Yamaguchi Y, Ishii G, Kojima M, et al. Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness. *J Thorac Oncol* 2010;5:1361–1368.
39. Taira T, Ishii G, Nagai K, et al. Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung. *Lung Cancer* 2012;76:423–430.
40. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. *Arch Pathol Lab Med* 2013;137:685–705.
41. Kadota K, Nitadori J, Rekhtman N, Jones DR, Adusumilli PS, Travis WD. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. *Am J Surg Pathol* 2015 [Epub ahead of print].
42. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. *Clin Cancer Res* 2012;18:1167–1176.
43. Kadota K, Villena-Vargas J, Yoshizawa A, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. *Am J Surg Pathol* 2014;38:448–460.
44. Lim HJ, Ahn S, Lee KS, et al. Persistent pure ground-glass opacity lung nodules  $\geq 10$  mm in diameter at CT scan: histopathologic comparisons and prognostic implications. *Chest* 2013;144:1291–1299.
45. Lee HY, Choi YL, Lee KS, et al. Pure ground-glass opacity neoplastic lung nodules: histopathology, imaging, and management. *AJR Am J Roentgenol* 2014;202:W224–W233.
46. Isaka T, Yokose T, Ito H, et al. Comparison between CT tumor size and pathological tumor size in frozen section examinations of lung adenocarcinoma. *Lung Cancer* 2014;85:40–46.
47. Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. *Radiology* 2013;266:304–317.
48. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. *Am J Surg Pathol* 2009;33:1752–1764.
49. Kadota K, Yeh YC, Sima CS, et al. The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. *Mod Pathol* 2014;27:690–700.
50. Mackinnon AC Jr, Luevano A, de Araujo LC, Rao N, Le M, Suster S. Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma. *Mod Pathol* 2014;27:1063–1072.
51. Warth A, Muley T, Kossakowski C, et al. Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma. *J Thorac Oncol* 2015;10:638–644.
52. Thunnissen E, Beasley MB, Borczuk AC, et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. *Mod Pathol* 2012;25:1574–1583.
53. Warth A, Cortis J, Fink L, et al.; Pulmonary Pathology Working Group of the German Society of Pathology. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. *Virchows Arch* 2012;461:185–193.
54. Nitadori J, Bograd AJ, Kadota K, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2 cm or smaller. *J Natl Cancer Inst* 2013;105:1212–1220.
55. Onozato ML, Kovach AE, Yeap BY, et al. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. *Am J Surg Pathol* 2013;37:287–294.
56. Kadota K, Nitadori J, Sima CS, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas. *J Thorac Oncol* 2015;10:806–814.
57. Warth A, Muley T, Kossakowski CA, et al. Prognostic impact of intra-alveolar tumor spread in pulmonary adenocarcinoma. *Am J Surg Pathol* 2015;39:793–801.
58. Loukeri AA, Kampolis CF, Ntokou A, Tsoukalas G, Syrigos K. Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis. *Clin Lung Cancer* 2015;16:15–23.
59. Klemperer SJ, Ignatius Ou SH, Costa DB, et al. The clinical use of genomic profiling to distinguish intrapulmonary metastases from synchronous primaries in non-small-cell lung cancer: a mini-review. *Clin Lung Cancer* 2015 [Epub ahead of print].
60. Murphy SJ, Aubry MC, Harris FR, et al. Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer. *J Clin Oncol* 2014;32:4050–4058.
61. Girard N, Deshpande C, Azzoli CG, et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. *Chest* 2010;137:46–52.
62. Girard N, Ostrovskaya I, Lau C, et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. *Clin Cancer Res* 2009;15:5184–5190.
63. Xue X, Liu Y, Pan L, et al. Diagnosis of multiple primary lung cancer: a systematic review. *J Int Med Res* 2013;41:1779–1787.
64. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients—based on a hospital study in China. *Eur J Surg Oncol* 2013;39:1262–1268.
65. Takahashi M, Shigematsu Y, Ohta M, Tokumasu H, Matsukura T, Hirai T. Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters. *J Thorac Cardiovasc Surg* 2014;147:54–59.
66. Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. *Lung Cancer* 2013;81:371–376.
67. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. *J Thorac Oncol* 2013;8:612–618.
68. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. *Ann Thorac Surg* 2014;98:453–458.
69. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. *J Thorac Oncol* 2013;8:52–61.
70. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. *J Thorac Oncol* 2011;6:1496–1504.
71. Woo T, Okudela K, Mitsui H, et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. *Pathol Int* 2012;62:785–791.
72. Cha MJ, Lee HY, Lee KS, et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. *J Thorac Cardiovasc Surg* 2014;147:921–928.e2.
73. Nitadori J, Bograd AJ, Kadota K, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2 cm or smaller. *J Natl Cancer Inst* 2013;105:1212–1220.

74. Ujjie H, Kadota K, Chaff J, et al. Solid predominant histologic subtype in resected stage I lung adenocarcinoma is an independent predictor of early, extrathoracic, multisite recurrence and of poor postrecurrence survival. *J Clin Oncol* 2015, in press.
75. Tsao MS, Marguet S, Le Teuff G, et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. *J Clin Oncol* 2015 [Epub ahead of print].
76. Brambilla C, Laffaire J, Lantuejoul S, et al. Lung squamous cell carcinomas with basaloid histology represent a specific molecular entity. *Clin Cancer Res* 2014;20:5777–5786.
77. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. Lyon: International Agency for Research on Cancer, 2005.
78. Brambilla E, Moro D, Veale D, et al. Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. *Hum Pathol* 1992;23:993–1003.
79. Moro-Sibilot D, Lantuejoul S, Diab S, et al. Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. *Eur Respir J* 2008;31:854–859.
80. Kim DJ, Kim KD, Shin DH, Ro JY, Chung KY. Basaloid carcinoma of the lung: a really dismal histologic variant? *Ann Thorac Surg* 2003;76:1833–1837.
81. Wang LC, Wang L, Kwak S, et al. Analysis on the clinical features of 22 basaloid squamous cell carcinoma of the lung. *J Cardiothorac Surg* 2011;6:10.
82. Herbst RS, Gandara DR, Hirsch FR, et al. Lung master protocol (Lung-MAP)-A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. *Clin Cancer Res* 2015;21:1514–1524.
83. Hwang DH, Szeto DP, Perry AS, Bruce JL, Sholl LM. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. *Arch Pathol Lab Med* 2014;138:626–635.
84. Rossi G, Mengoli MC, Cavazza A, et al. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. *Virchows Arch* 2014;464:61–68.
85. (NGM) CLCGPCNGM. A genomics-based classification of human lung tumors. *Sci Transl Med* 2013;5:209ra153.
86. Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type. *Cancer* 2014;120:2883–2892.
87. Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoid. *Ann Oncol* 2015;26:1604–1620.
88. Fernandez-Cuesta L, Peifer M, Lu X, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. *Nat Commun* 2014;5:3518.
89. Pelosi G, Rindi G, Travis WD, Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. *J Thorac Oncol* 2014;9:273–284.
90. Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. *Am J Surg Pathol* 2005;29:179–187.
91. Walts AE, Ines D, Marchevsky AM. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. *Mod Pathol* 2012;25:1258–1264.
92. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. *Am J Surg Pathol* 1998;22:934–944.
93. Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis. *Surgery* 2012;152:397–402.
94. Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. *Int J Cancer* 2009;125:2479–2482.
95. Pelosi G, Scarpa A, Manzotti M, et al. K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. *Mod Pathol* 2004;17:538–546.
96. Chang YL, Wu CT, Shih JY, Lee YC. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. *Ann Surg Oncol* 2011;18:2952–2960.
97. Kaira K, Horie Y, Ayabe E, et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. *J Thorac Oncol* 2010;5:460–465.
98. Leone A, Graziano P, Gasbarra R, et al. Identification of EGFR mutations in lung sarcomatoid carcinoma. *Int J Cancer* 2011;128:732–735; author reply 736.
99. Lee S, Kim Y, Sun JM, et al. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. *J Cancer Res Clin Oncol* 2011;137:1203–1211.
100. Dacic S, Finkelstein SD, Sasatomi E, Swalsky PA, Yousem SA. Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping. *Am J Surg Pathol* 2002;26:510–516.
101. Holst VA, Finkelstein S, Colby TV, Myers JL, Yousem SA. p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis. *Am J Surg Pathol* 1997;21:801–811.
102. Pardo J, Aisa G, de Alava E, et al. Primary mixed squamous carcinoma and osteosarcoma (carcinosarcomas) of the lung have a CGH mapping similar to primitive squamous carcinomas and osteosarcomas. *Diagn Mol Pathol* 2008;17:151–158.
103. Pelosi G, Gasparini P, Cavazza A, et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a non-random amplification of anaplastic lymphoma kinase (ALK) gene. *Lung Cancer* 2012;77:507–514.
104. Toyokawa G, Takenoyama M, Taguchi K, et al. The first case of lung carcinosarcoma harboring in-frame deletions at exon19 in the EGFR gene. *Lung Cancer* 2013;81:491–494.
105. Macher-Goeppinger S, Penzel R, Roth W, et al. Expression and mutation analysis of EGFR, c-KIT, and  $\beta$ -catenin in pulmonary blastoma. *J Clin Pathol* 2011;64:349–353.
106. Nakatani Y, Masudo K, Miyagi Y, et al. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. *Mod Pathol* 2002;15:617–624.
107. Sekine S, Shibata T, Matsuno Y, et al. Beta-catenin mutations in pulmonary blastomas: association with morule formation. *J Pathol* 2003;200:214–221.
108. Bodner SM, Koss MN. Mutations in the p53 gene in pulmonary blastomas: immunohistochemical and molecular studies. *Hum Pathol* 1996;27:1117–1123.
109. Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. *Clin Cancer Res* 2012;18:5773–5779.
110. French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. *J Clin Oncol* 2004;22:4135–4139.
111. French CA. Demystified molecular pathology of NUT midline carcinomas. *J Clin Pathol* 2010;63:492–496.
112. Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. *Am J Surg Pathol* 2009;33:984–991.
113. Schwartz BE, Hofer MD, Lemieux ME, et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. *Cancer Res* 2011;71:2686–2696.
114. Devouassoux-Shisheboran M, Hayashi T, Linnoila RI, Koss MN, Travis WD. A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium. *Am J Surg Pathol* 2000;24:906–916.
115. Chan AC, Chan JK. Pulmonary sclerosing hemangioma consistently expresses thyroid transcription factor-1 (TTF-1): a new clue to its histogenesis. *Am J Surg Pathol* 2000;24:1531–1536.
116. Niho S, Suzuki K, Yokose T, Kodama T, Nishiwaki Y, Esumi H. Monoclonality of both pale cells and cuboidal cells of sclerosing hemangioma of the lung. *Am J Pathol* 1998;152:1065–1069.
117. Dal Cin P, Kools P, De Jonge I, Moerman P, Van de Ven W, Van den Bergh H. Rearrangement of 12q14-15 in pulmonary chondroid hamartoma. *Genes Chromosomes Cancer* 1993;8:131–133.
118. Fletcher JA, Longtine J, Wallace K, Mentzer SJ, Sugarbaker DJ. Cytogenetic and histologic findings in 17 pulmonary chondroid

- hamartomas: evidence for a pathogenetic relationship with lipomas and leiomyomas. *Genes Chromosomes Cancer* 1995;12:220–223.
119. Xiao S, Lux ML, Reeves R, Hudson TJ, Fletcher JA. HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma. *Am J Pathol* 1997;150:901–910.
  120. Tomashefski JF Jr. Benign endobronchial mesenchymal tumors: their relationship to parenchymal pulmonary hamartomas. *Am J Surg Pathol* 1982;6:531–540.
  121. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. *Proc Natl Acad Sci U S A* 2000;97:6085–6090.
  122. Martignoni G, Pea M, Reghellin D, et al. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. *Arch Pathol Lab Med* 2010;134:33–40.
  123. D'Armiento J, Imai K, Schiltz J, et al. Identification of the benign mesenchymal tumor gene HMGA2 in lymphangioleiomyomatosis. *Cancer Res* 2007;67:1902–1909.
  124. McCormack FX, Travis WD, Colby TV, Henske EP, Moss J. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. *Am J Respir Crit Care Med* 2012;186:1210–1212.
  125. Flieder DB, Travis WD. Clear cell “sugar” tumor of the lung: association with lymphangioleiomyomatosis and multifocal micronodular pneumocyte hyperplasia in a patient with tuberous sclerosis. *Am J Surg Pathol* 1997;21:1242–1247.
  126. Pilieri SA, Cavazza A, Schiavina M, et al. Clear-cell proliferation of the lung with lymphangioleiomyomatosis-like change. *Histopathology* 2004;44:156–163.
  127. Lawson K, Maher TM, Hansell DM, Nicholson AG. Successful treatment of progressive diffuse PComatosis. *Eur Respir J* 2012;40:1578–1580.
  128. Maruyama H, Seyama K, Sobajima J, et al. Multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis with a TSC2 gene. *Mod Pathol* 2001;14:609–614.
  129. Gaffey MJ, Mills SE, Ritter JH. Clear cell tumors of the lower respiratory tract. *Semin Diagn Pathol* 1997;14:222–232.
  130. Chen YB, Guo LC, Huang JA, Ji C, Ling CH. Clear cell tumor of the lung: a retrospective analysis. *Am J Med Sci* 2014;347:50–53.
  131. Gaffey MJ, Mills SE, Zarbo RJ, Weiss LM, Gown AM. Clear cell tumor of the lung. Immunohistochemical and ultrastructural evidence of melanogenesis. *Am J Surg Pathol* 1991;15:644–653.
  132. Lantuejoul S, Isaac S, Pinel N, Negoescu A, Guibert B, Brambilla E. Clear cell tumor of the lung: an immunohistochemical and ultrastructural study supporting a pericytic differentiation. *Mod Pathol* 1997;10:1001–1008.
  133. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. *Nat Genet* 2005;37:19–24.
  134. Anderson T, Zhang L, Hameed M, Rusch V, Travis WD, Antonescu CR. Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. *Am J Surg Pathol* 2015;39:132–139.
  135. Lau K, Massad M, Pollak C, et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. *Chest* 2011;140:1312–1318.
  136. Mendlick MR, Nelson M, Pickering D, et al. Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma. *Am J Surg Pathol* 2001;25:684–687.
  137. Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. *Genes Chromosomes Cancer* 2011;50:644–653.
  138. Patel NR, Salim AA, Sayeed H, et al. Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants. *Histopathology* 2015 [Epub ahead of print].
  139. Tanas MR, Shoner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. *Sci Transl Med* 2011;3:98ra82.
  140. Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. *Genes Chromosomes Cancer* 2013;52:775–784.
  141. Bagan P, Hassan M, Le Pimpec Barthes F, et al. Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma: a review of the literature. *Ann Thorac Surg* 2006;82:2010–2013.
  142. Nicholson AG, Baandrup U, Florio R, Sheppard MN, Fisher C. Malignant myxoid endobronchial tumour: a report of two cases with a unique histological pattern. *Histopathology* 1999;35:313–318.
  143. Thway K, Nicholson AG, Lawson K, et al. Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion: a new tumor entity. *Am J Surg Pathol* 2011;35:1722–1732.
  144. Thway K, Nicholson AG, Wallace WA, Al-Nafussi A, Pilling J, Fisher C. Endobronchial pulmonary angiomatoid fibrous histiocytoma: two cases with EWSR1-CREB1 and EWSR1-ATF1 fusions. *Am J Surg Pathol* 2012;36:883–888.
  145. Thway K, Fisher C. Tumors with EWSR1-CREB1 and EWSR1-ATF1 fusions: the current status. *Am J Surg Pathol* 2012;36:e1–e11.
  146. Fletcher CDM, Antonescu C, Heim S, Hornick JL. Myoepithelioma/myoepithelial carcinoma/mixed tumor. In: CDM Fletcher, JA Bridge, PCW Hogendoorn, F Mertens (Eds.). WHO Classification of Tumours of Soft Tissue and Bone. 4th Ed. Lyon: IARC, 2013:208–209.
  147. Hornick JL, Fletcher CD. Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. *Am J Surg Pathol* 2003;27:1183–1196.
  148. Hysi I, Watez H, Benhamed L, Porte H. Primary pulmonary myoepithelial carcinoma. *Interact Cardiovasc Thorac Surg* 2011;13:226–228.
  149. Kourda J, Ismail O, Smati BH, Ayadi A, Kilani T, El Mezni F. Benign myoepithelioma of the lung - a case report and review of the literature. *Cases J* 2010;3:25.
  150. Masuya D, Haba R, Huang CL, Yokomise H. Myoepithelial carcinoma of the lung. *Eur J Cardiothorac Surg* 2005;28:775–777.
  151. Sarkaria IS, DeLair D, Travis WD, Flores RM. Primary myoepithelial carcinoma of the lung: a rare entity treated with parenchymal sparing resection. *J Cardiothorac Surg* 2011;6:27.
  152. Antonescu CR, Zhang L, Chang NE, et al. EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. *Genes Chromosomes Cancer* 2010;49:1114–1124.
  153. Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. *Ann Rheum Dis* 2013;72:1691–1695.
  154. Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. *Blood* 2014;124:483–492.
  155. Arnaud L, Pierre I, Beigelman-Aubry C, et al. Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. *Arthritis Rheum* 2010;62:3504–3512.
  156. Haroche J, Arnaud L, Cohen-Aubart F, et al. Erdheim-Chester disease. *Curr Rheumatol Rep* 2014;16:412.
  157. Brun AL, Touitou-Gottenberg D, Haroche J, et al. Erdheim-Chester disease: CT findings of thoracic involvement. *Eur Radiol* 2010;20:2579–2587.
  158. Rush WL, Andriko JA, Galateau-Salle F, et al. Pulmonary pathology of Erdheim-Chester disease [In Process Citation]. *Mod Pathol* 2000;13:747–754.
  159. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. *Blood* 2012;120:2700–2703.
  160. Chetritt J, Paradis V, Dargere D, et al. Chester-Erdheim disease: a neoplastic disorder. *Hum Pathol* 1999;30:1093–1096.
  161. Vencio EF, Jenkins RB, Schiller JL, et al. Clonal cytogenetic abnormalities in Erdheim-Chester disease. *Am J Surg Pathol* 2007;31:319–321.
  162. Gong L, He XL, Li YH, et al. Clonal status and clinicopathological feature of Erdheim-Chester disease. *Pathol Res Pract* 2009;205:601–607.
  163. Tzoulis C, Schwarzmüller T, Gjerde IO, et al. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. *BMC Res Notes* 2015;8:171.
  164. Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. *J Clin Oncol* 2015;33:411–418.